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Within the last few years a substantial amount
of literature has been published of both evi-
dence and argument concerning real injury
and serious threats to human health from
exposures to toxic substances and persistent
toxic substances. These publications have
emerged in fairly rapid succession from inde-
pendent scientists, government agencies, and
nongovernment public interest groups (1–11).
The most recent of these studies focused
on the implications of environmental conta-
minants, particularly neurotoxic chemicals,
for children’s development and health.
Researchers realize that children are not just
“little adults,” and the studies suggest that the
developing fetus, infant, and child are partic-
ularly vulnerable to the toxic effects of chemi-
cals. Together with emerging evidence that
developmental disabilities are common in
North American children, affecting millions,
this new evidence has created a new area of
public health concern and science.
With this information as a backdrop, the
International Joint Commission’s (IJC) Great
Lakes Science Advisory Board, Workgroup
on Ecosystem Health (SAB-WGEH), selected
several of the effects or outcomes, suggested
by the research results as candidates for envi-
ronmental causation, for analysis from the
societal and economic perspectives. In this
light, several things should be noted at the
outset. First, the chosen case studies are based
on the collective professional judgment of the
SAB-WGEH, as people knowledgeable of the
scientiﬁc background and evidence on human
exposure to many toxic and persistent toxic
substances, on mechanisms of action, experi-
mental work, effects in wildlife, environmen-
tal etiology, and other studies that suggest
that environmental agents cause clinical
disease in humans and that children are at
particular risk.
Second, this report must be seen within
the context of the workshop as a whole,
which covered several of the case studies in
greater detail. Thus, this report takes those
case studies as givens and, aside from
selected references consulted to show how
certain chosen effects may be linked and to
motivate some of the analysis, it is beyond
the scope of this report to report a full
review of the evidence.
Third, this report makes no deﬁnite attri-
bution of any of the case-study effects to any
particular environmental toxic substance, per-
sistent toxic substance, or other pollutant or
agent. However, a great many toxic and pos-
sibly neurotoxic agents circulate freely in the
environment; all people and potential prog-
eny are constantly exposed to these complex
mixtures and have been for many decades,
making it neither reasonable nor prudent to
assume a cumulative zero effect on the
human population.
Also, this article makes no specific,
analytical determination of the proportion of
these case-study effects or diseases and their
health and economic costs that may be
explained by environmental or other causes.
Rather, reasonable and alternative hypotheses
are made about these proportions solely to
illustrate the potential societal and economic
costs, consequences, and significance. The
focus on the economic and societal dimen-
sions of health costs is highly relevant
because these costs are an enormous and
growing ﬁnancial burden on society. 
The selected case-study effects include
diabetes; neurotoxicity presented as
Parkinson’s disease (PD); neurodevelopmen-
tal effects in children, with consideration of
hypothyroidism as one possible mechanism of
causation; and neurodevelopmental effects on
the intelligence quotient (IQ). Where possi-
ble, costs associated with sequelae possibly
related to neurodevelopmental effects and
hypothroidism or other neurotoxic mecha-
nisms, such as autism, attention deﬁcit-hyper-
activity disorder (ADHD), dyslexia, and
violent behavior are also covered. These
effects or outcomes reﬂect that children grow
up to be adults, that some effects do not
appear until later in life, and that some sub-
populations are at higher risk than others. 
Methods and Materials
The methods used involve the examination of
several lines of evidence, including empirical,
methodological, and theoretical. First, the lit-
erature was reviewed to determine the evi-
dence leading to the published concerns that
exposures to environmental agents, particu-
larly persistent toxic substances, are plausible
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risk factors in children, and the chosen effects
or outcomes. 
Second, literature was reviewed to gauge
and assess the extent to which approaches and
methodologies to measure such ﬁnancial and
economic costs and impacts, in general, are
developed, and the extent to which case
studies on our chosen outcomes have been
undertaken. Where such methodologies and
case studies existed, they were either cited,
adapted, updated, or expanded.
Third, where no existing studies were
found that evaluate or analyze cost for any of
the selected effects, primary data sources were
searched for, and where possible, estimates
were made using the existing methodologies
and/or economic theory.
Throughout this exercise, efforts were
made to develop independent estimates for
Canada or Canadian jurisdictions, and the
United States. In some cases, cost estimates
for other countries are reported in the litera-
ture, and these are cited here for comparison. 
Results—General
This section is intended to provide an
overview of the most general and prelimi-
nary findings of this study and to provide
some context for the motivation behind the
work. In general, the literature describing
approaches and methodologies to estimate
the societal and economic costs of illness
and disease and the counterpart estimation
of the public health benefits of reducing or
eliminating exposure to toxic agents is well
developed (12–17). However, the applica-
tion of these tools to actually describe such
costs, and to value such beneﬁts, is limited. 
Reducing or eliminating exposures costs
money, so people continue to be exposed.
However, maintaining exposures also has its
costs; but it is more difﬁcult and expensive to
measure them, albeit some attempts have
been made in certain instances, for example,
with lead (13,17,18) and, more recently, with
air pollution (16). In the Great Lakes region,
there is no systematic and comprehensive
effort to estimate the costs of the effects on
human health of exposures to toxic sub-
stances or persistent toxic substances.
The emergent evidence and the resulting
concerns expressed in the literature by both
government and nongovernment bodies and
agencies, and by scientists, can be seen,
together with data on the costs of health care
in Canada and the United States. The evi-
dence of injury and the healthcare and eco-
nomic costs correlate with and reflect each
other. However, as an indicator of damage,
medical expenditures are only a proxy mea-
sure that underestimates the value of avoiding
an illness or preventing a disease.
In the United States, actual national
health expenditures (public and private)
totaled almost $1.1 trillion in 1997 ($1.276
trillion in 1999 dollars), or almost $4,000
($4,640 in 1999 dollars) per person, and
13.5% of the gross domestic product (GDP).
These expenditures are projected to total $2.2
trillion by 2008, or almost $7,200 per person,
and 16.2% of GDP (19).
In Canada, actual national health expen-
ditures (public and private) totaled almost
$77 billion in 1997, or just over $2,500 per
person, and 8.9% of GDP. These expendi-
tures in 1999 amounted to about $86 billion,
or more than $2,800 per person, and 9.2% of
GDP (20). 
In Ontario, the 1994 total health expendi-
ture was almost $28.5 billion, or about $2,600
per person. Ontario’s expenditure is forecast
almost $3,000 per person in 1999 (20).
These very large costs of healthcare vividly
underline the importance of considering
them in the context of environmentally
caused disease and the need to consider the
linkages between disease prevention and pol-
lution prevention, reduction, and elimina-
tion. However, as noted above, these proxy
measures are inadequate in themselves, as
they are usually large underestimates of the
true value of avoiding illness or preventing
disease (17). 
Merely taking account of these direct
costs of illness does not adequately tally the
economic costs and consequences. Other
costs are incurred in addition to those from
direct medical intervention, and from the
viewpoint of the economic value of avoiding
disease, or maintaining health, people may
indicate a willingness to pay in excess of the
direct medical costs (12,14,16).
Other direct expenditures also include
those that are nonmedical, such as food,
transportation, lodging and institutional care,
compensatory educational costs, family care
and in-home education, home aids, and
clothing. Another category of costs includes
other economic, financial, personal, and
social impacts and costs that are equally
important although indirect. 
Indirect costs are those that occur because
of loss of human potential or loss of life or
livelihood due to sickness, disability, or death.
Such costs may occur because of decreased
earning ability when working, or because of
long-term disability that necessitates a change
in type of work, or even the inability to work
altogether. For example, these may be related
to a decrease in productivity due to absence
from work or they may be related to decreased
earnings potential because of potential disabil-
ities, lost earnings due to premature mortality,
and increased insurance costs.
Other intangible costs, even though difﬁ-
cult to measure, are real nonetheless. These
include the costs of pain and suffering, dread
and the type of death, grief, loss of quality
and enjoyment of life, loss of life years, loss of
companionship and social contact, and other
nonﬁnancial outcomes of disease and medical
care, including side effects of medication. 
We can use some economic techniques or
tools in our attempt to value many but per-
haps not all of these costs and losses. These
tools include accounting for lost earnings or
income, for the costs of averting behavior or
defensive expenditures, and for compensatory
wages or wage differentials. These tools rely
on market-based prices and personal actions
that can be readily measured and that are
familiar to people. 
Other tools, which do not use the so-
called revealed preferences of market-based
signals and prices, rely on surveys that
attempt to elicit so-called stated
preferences.These try to measure what people
state they would be willing to pay to avoid an
illness or disease (or more frequently, a small
increase in the risk of an illness or disease), or
what they say they would be willing to accept
in compensation for an illness or disease or a
small increase in the risk of said condition.
These survey-based techniques or tools of val-
uation are known as contingent valuation
analysis and conjoint analysis. They have
been used in Canada to value the health
effects of air pollution (16), and there have
been other applications not referenced here.
It would be interesting to ask what people are
willing to pay to avoid, or what they are will-
ing to accept in compensation for having, a
child who is neurodevelopmentally disabled. 
To summarize the general results, the con-
cerns about the effects on human health of
exposures to toxic substances and persistent
toxic substances are substantively based on the
weight of evidence and on the emerging sci-
ence. In addition, the overall or total health
expenditures incurred in both Canada and the
United States are an enormous and substan-
tially growing burden. These societal costs
directly reﬂect a disease burden in both adults
and children and are thought to contain an
unknown component with environmental
causation as a hypothetical candidate, since
known risk factors cannot account for it. 
While this basic conclusion has been vari-
ously stated in several reports and scientific
publications, it is perhaps best put in a recent
(June 2000) scientiﬁc publication of the U.S.
Public Health Service, National Institutes of
Health, which states, 
An association has been found between
exposure to toxic chemicals and various
neuro-developmental disorders such as
learning disabilities, intellectual retardation,
dyslexia, attention deﬁcit/hyperactivity dis-
order, autism, and propensity to violence.
Timing of exposure can be critical to the
development of these disorders that cur-
rently affect millions of children. (21)Societal costs of exposure to toxic substances
It is also evident that the tools and
techniques to estimate the societal and eco-
nomic costs and impacts of environmental
disease exist, have been used in a number of
instances, and have a large potential in other
applications. 
Results—Case Studies
Diabetes
Diabetes mellitus is a chronic and potentially
disabling disease that represents a major pub-
lic health and clinical concern. It is a major
source of morbidity, mortality, and
economic expense in both the United States
and Canada, as well as in other industrial
countries (22–29).
People with diabetes are at increased risk for
chronic complications speciﬁc to the disease,
including cardiovascular disease, stroke, high
blood pressure, lower limb amputations, kidney
disease, eye disease (blindness), peripheral neu-
ropathy, and other general medical conditions.
Consequently, people with diabetes have more
frequent and intensive encounters with the
health care system (22,25).
In 1997, an estimated 10.3 million
Americans reported they had diabetes and
about 5.4 million have undiagnosed diabetes.
Some uncertainty exists about these preva-
lence estimates, with suggestions that the dis-
ease could affect as much as 10% of the
population. Other reports indicate higher
rates up to 20% in people 50 years of age or
older, with even higher rates in native North
Americans, many people of Asian descent,
and blacks (22,25).
In Canada, estimates of prevalence rates
are similar, with similar uncertainties. On the
basis of the 1996/1997 survey data and
extrapolation of American data, the preva-
lence of diagnosed diabetes in Canada is
3.2% of the population over 12 years of age,
or almost 800,000 people; including undiag-
nosed cases brings the total to 4.9–5.8% of
the population over 12 years of age, or 1.2
million to 1.4 million people (25).
Other estimates put diagnosed diabetes at
4.5% (1.3 million), and 5% (1.5 million) of
Canadians (30). Depending on the report
consulted, anywhere from another 50–100%
of the diagnosed cases may be matched by an
undiagnosed case.
On the basis of the 1996/1997 survey
data, native North Americans in Canada have
triple the age-adjusted prevalence rate found
in the general population, or about 60,000
cases, including undiagnosed (25).
Prospects for the future are not good. As
the population as a whole ages, the prevalence
will reﬂect this and is expected to increase in
Canada to about 3 million by 2010 (30).
Speciﬁc projections for the United States were
not found in this review; however, it is expected
to be similar to Canada’s, and the World
Health Organization estimates a doubling of
world prevalence of diabetes by 2010 (30). 
Some might argue that the increase in
incidence or prevalence that accompanies the
aging of the population is not an environ-
mental effect. However, that argument raises
questions, and it seems prudent to allow for
the possibility that the age-speciﬁc incidence
rates (the annual number of new cases), and
therefore the prevalence or total number of
cases could increase in the future because of
environmental causes. That is the implicit
intent here in referring to projections of the
future: the burden of the disease is expected
to become heavier, and this can mask envi-
ronmental effects.
For example, we do not know how long
an environmental effect might take to be
expressed in clinical disease—a possible
latency—and it is possible that older people
are more susceptible to environmental effects.
In other words, it does not seem reasonable to
assert that there is absolutely no environmen-
tal effect component in the increases in inci-
dence or prevalence that might appear as the
population ages. 
Economic cost—case study. United States.
For this review we located several studies that
demonstrate methods and estimate the eco-
nomic burden for several jurisdictions. The
most pertinent, complete, and up-to-date is a
1998 report from the American Diabetes
Association (ADA), which estimates the
direct medical and indirect expenditures
attributable to diabetes in 1997 for the
United States (22). 
The methodology is consistent with other
cost-of-illness studies in which the economic
costs consist of healthcare expenditures and
the value (measured as foregone earnings) of
productivity lost due to disability and prema-
ture death. The direct medical costs consisted
of two components: the ﬁrst includes medical
expenses attributed to diabetes without com-
plications, and to acute metabolic conditions
due to diabetes; the second includes the
attributable expenditures associated with the
excess prevalence of chronic complications of
diabetes, and with the excess prevalence of
general medical conditions, among people
with diabetes.
Table 1 provides details about the health-
care expenditures attributable to diabetes by
various factors, as reported by the ADA (22).
Table 2 provides data on the total attributable
economic costs, including the foregone pro-
ductivity measures based on lost earnings due
to disability and death.
The results reveal the following: Total
direct medical and indirect expenditures
(including the value of lost productivity)
attributable to diabetes in 1997 were esti-
mated at $98 billion. Updating these costs
from 1997 to 1999 dollars, using the
Medical Care component of the U.S.
Consumer Price Index, involves an inﬂation
factor of 1.16 (31), which would bring the
total to $113.7 billion.
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Table 1. Health care expenditures attributed to diabetes by age, race, condition, and type of service, 1997, in mil-
lions of 1999 U.S. dollars.a,b
Nursing home,  Total direct 
Inpatient All home healthcare,  medical
Medical condition hospital outpatient and hospice expenditures
Uncomplicated diabetes and  3,347 3,522 2,039 8,908
acute metabolic conditions
Excess prevalence of related  11,295 833 1,597 13,736
chronic complicationsc
General medical conditions 17,205 8,278 3,073 28,556
Total cost 31,847 12,632 6,709 51,200
Age and race
<45 2,915 1,775 41 4,731
<65, nonwhite 4,312 1,537 124 5,973
<65, white 6,941 3,867 176 10,986
≥65, nonwhite 4,943 1,099 1,029 7,070
≥65, white 15,650 3,611 5,387 24,648
Note: Numbers may not sum because of rounding.
aAll data in this table are indexed using the medical component of the U.S. Consumer Price Index. bThis table is a modification of
Table 6, “Healthcare expenditures attributable to diabetes by age, race, condition, and type of service,” in reference (22). cRelated
chronic complications include neurologic disease, peripheral vascular disease, cardiovascular disease, renal disease, ophthalmic dis-
ease, and other chronic complications.
Table 2. Total economic costs of diabetes by age and
race, 1997, in millions of 1999 U.S. dollars.a,b
Direct
medical Lost Total
Age, race expenditures productivity cost
<45, all 4,731 5,868 10,599
<65, all 16,988 57,143 74,131
<65, white 10,986 11,598 22,584
<65, nonwhite 7,368 4,174 11,542
≥65, all 31,756 5,516 37,272
≥65, white 24,648 3,340 27,987
≥65, nonwhite 7,070 567 7,637
Total 51,200 62,645 113,856
aAll data in this table are indexed using the medical compo-
nent of the U.S. Consumer Price Index. bThis table is a modifi-
cation of Table 7, “Attributable economic cost of diabetes,”in
reference (22).Muir and Zegarac
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Direct medical expenditures alone totaled
$51.2 billion in 1999 dollars. This amount
was composed of $8.93 billion for diabetes
and acute glycemic care; $13.69 billion
because of excess prevalence of related
chronic complications; and $28.54 billion
because of the excess prevalence of general
medical conditions. Two-thirds of all medical
costs were attributable to elderly people (>65
years of age).
Table 2 shows that attributable indirect
costs totaled $62.65 billion. This consisted of
$19.66 billion resulting from premature mor-
tality and $42.98 billion from disability
(numbers are rounded).
Total medical expenditures (inflated to
1999 U.S. dollars) incurred by people with
diabetes totaled $90.13 billion, or $11,682
per capita, compared with $3,096 for people
without diabetes (22). It is clear that the eco-
nomic burden of diabetes in the United
States is immense.
Canada. There was no comprehensive
economic costs study similar to the ADA
report available for Canada. A 1999 report by
Health Canada (25), made only passing men-
tion to the economic burden of diabetes, refer-
ring to only one incomplete study of the
Canadian experience, and then referred to and
extrapolated the work of the ADA cited above. 
The incomplete study cited estimated that
the burden of diabetes medical care alone was
about $1.1 billion annually in 1993 (25).
Updating the cost from 1993 to 1999 dollars,
using the Health and Personal Care compo-
nent of the Canadian Consumer Price Index,
involves an inﬂation factor of 1.075 (32), and
this would bring the total to $1.18 billion
Canadian dollars. The study was termed
incomplete because none of the excess preva-
lence of complications closely tied to diabetes,
or of the excess prevalence of general medical
conditions among diabetics, or of the lost
productivity due to morbidity and mortality,
were included.
Because the data for Canada on preva-
lence, hospital and medical care utilization,
and associated morbidity and mortality,
roughly parallel the situation in the United
States, the Health Canada study scaled the
U.S. economic cost estimates in proportion
to the population (Canadian population is
approximately one tenth that of the United
States). Thus, the costs in Canada may be as
high as 10% of the costs identiﬁed above for
the United States, or about $14.157 billion
(1999 CDN dollars) annually, in total. This
includes Canadian exchange rate adjustment
to the 1997 U.S. cost and then inflation to
1999 dollars.
Data on patient visits to physicians in
Canada in 1999 indicate that diabetes was the
second leading diagnosis, behind hyper-
tension, and followed by depression.
Prescription drugs dispensed for diabetes
ranked in 11th place in 1999, totaling almost
9 million prescriptions (33). 
Ontario. The Universal Health Care sys-
tem in Canada, or Medicare, provides that
each province in Canada administer the deliv-
ery of covered health care in its own jurisdic-
tion. In Ontario, this is known as the Ontario
Health Insurance Plan (OHIP). In Ontario,
data on hospital usage by detailed medical
code were published annually in a report
until the 1991/1992 edition, when the report
was discontinued.
Recourse was made to special requests to
the Health Planning Branch of the Ontario
Ministry of Health (34) for data on public
expenditures on inpatient and outpatient hos-
pital usage, and for physician usage, for treat-
ments directly involving all the effects
considered in this article, including, of
course, diabetes. 
These economic costs pertain only to
publicly (OHIP) funded medical expendi-
tures directly attributable to diabetes and
some involving diabetes with certain compli-
cations. Unlike in the ADA report cited
above, the OHIP does not publish an
accounting of excess prevalence of chronic
complications of diabetes, of the excess preva-
lence of general medical conditions among
people with diabetes, of the numerous possi-
ble medical expenditures paid for privately, or
of the productivity losses due to disability and
early mortality.
According to the data provided by the
Ontario Ministry of Health, total inpatient
and outpatient hospital costs incurred by
OHIP in Ontario for diabetes averaged about
$54.4 million (CDN dollars) annually over
the 1996–1998 period. The same source indi-
cates that OHIP expenditures for doctors
diagnosing diabetes, including complications,
totaled about $55.3 million for the
1998/1999 reporting year (34).
Parkinson’s Disease
General results. Parkinson’s disease (PD) is a
chronic, progressive neurologic disorder
affecting about 400,000 to 600,000 people,
predominantly 45 years of age or older, in the
United States. Reported prevalence is esti-
mated between 200 and 300 per 100,000
population, and incidence rates vary from 5
to 24 per 100,000 per year, although studies
have found that many people with PD go
undiagnosed (35,36). The prevalence of PD
in the United States is projected to increase to
about 1.3 million (middle estimate) by the
year 2040, as the susceptible age cohorts grow
but assuming no change in current rates (37).
However, death rates from PD are increas-
ing, so this prevalence rate projection may be
an underestimate (37). It has been noted in
the literature that a possible interaction
between aging and exposure to neurotoxic
agents is of critical concern (38,39). The
potential exists for agents to induce delayed
neurotoxicity years after cessation of exposure
or as a result of low-level exposure over the life
span. As the large cohort of baby boomers
ages, any added increase in dysfunction as a
consequence of exposure to neurotoxic agents
will place additional burdens on the health-
care system. 
Several scientiﬁc papers reported on cost-
of-illness studies; however, only one pertained
to the United States, and none was located for
Canada (35,40,41). Other papers described
the social costs (42) and the health burdens
(36) of PD. Another described projected neu-
rodegenerative mortality, including deaths
from PD, in the United States from 1990 to
2040 (37). All these studies underlined the
serious and important health, social, and eco-
nomic burdens of PD. As a chronic, disabling
disease, PD is likely to induce significant
direct medical costs, as well as considerable
indirect costs. Despite pharmacologic and sur-
gical intervention, the disease leads to severe
disability, and mortality. Disability can result
in devastating, personal economic conse-
quences. Up to 15% of patients are unable to
work after 5 years, and up to 80% after 9
years of illness. Special equipment needs and
housing adaptations lead to even more costs
on already ﬁnancially stressed families.
In addition to the direct and indirect
financial and economic costs, a substantial
personal burden must be borne by the
affected individuals and their families. This
takes the form of a severe impairment to the
quality of life and to personal and social
function, with accompanying embarrassment
and numerous other consequences, due to
the adverse physical and psychiatric effects of
the disease, including possible declines in
mental health. 
Overall, the social effect of PD can be
described as premature aging of the individu-
als affected, impinging much more heavily on
the younger PD patients. This is a reminder
of the point about the potential for neuro-
toxic agents to accelerate the aging process
and the decline in the functional capacity of
the brain, and the potential for long-latency,
delayed neurotoxicity raised above (38,39).
Few articles in the literature address these per-
sonal and family consequences. 
Economic costs—case study. Ontario.
According to information provided by the
Ontario Ministry of Health, total inpatient
and outpatient hospital costs incurred by
OHIP in Ontario for PD averaged about
$14.2 million (CDN dollars) annually
between 1996 and 1998. The represents an
average cost per case of almost $16,400 (34).
The same source indicates that OHIP expen-
ditures for doctors totaled almost $3.5Societal costs of exposure to toxic substances
million for the 1998/1999 reporting year
(34). No information was available for drug-
related expenses or for any of the many other
ﬁnancial, economic, and social costs attribut-
able to PD for Ontario. 
United States and other countries. One
U.S. study used the 1987 National Medical
Expenditure Survey as a source of popula-
tion-based information about health resource
use, medical expenditure, and health status
(35). Forty-three patients with PD were iden-
tiﬁed, and each was matched with 3 individu-
als without PD to estimate the costs
attributable to PD. The control individuals
were patients who had other chronic medical
conditions but who did not have PD.
These data show the serious health and
economic burdens of PD. People with PD
had decreased health status, increased health
expenditures, and lost productivity relative to
controls. However, the article noted that
because of small sample size, which inade-
quately represented people in the earliest and
in the most advanced stages of PD and
showed considerable variability in the case–
control groups, these estimates of the eco-
nomic burden must be used with caution.
Patients with PD accounted for signifi-
cantly greater mean total expenditure than
controls for the year of the study (1987).
Updating those costs to 1999 U.S. dollars
brings the mean expenditure for PD patients
to $22,914 (median $6,436; range $640 to
$226,171) and the mean for the control
group to $10,458 (no other data provided for
controls). The higher expenditure was mainly
due to higher hospital expenditures (mean for
PD $15,980, range $0–$208,905; mean for
control $5,180). The apparent high mean
cost for the controls is related to their being
patients with other chronic illnesses, with the
result that healthy, illness-free individuals,
who may have had near zero or very low
costs, are not represented. 
Also, PD patients had higher mean pre-
scription expenditures ($882 1999 U.S. dol-
lars higher) and higher home-health provider
expenditures ($441, 1999 U.S. dollars higher)
compared to those of controls. PD patients
also had a higher mean length of hospital stay
than the controls at 31.6 versus 11 nights,
respectively. The mean for patients with PD
was highly influenced by the small sample
sizes and by two patients who spent 112 and
143 nights, respectively, in the hospital.
Social function items that involved visits
out of the house showed significant impair-
ment among patients with PD. Productivity
measures were also significantly lower for
patients with PD. None of these items were
provided with an economic measure,
although such measures are very important
repercussions of the disease on the patients
and on society at large.
In a study from France (41), Le Pen et al.
prospectively observed a large sample of
patients with PD for 6 months. This study
veriﬁed the importance of falls and the strong
association between health expenditures and
the intensity of clinical motor fluctuations.
Average 6-month costs for patients with ﬂuc-
tuations was $3,513 (1999 U.S. dollars) com-
pared to $1,912 for patients without. If
patients were seen by a neurologist the costs
were higher, at $3,537 compared to $1,556
for those who did not see a specialist. These
numbers differ from the data in Table 3 for
the Le Pen study, which are based on the
mean health expenditures for all 294 PD
patients in the study rather than the sub-
categories described above.
Recent advances in drug therapy may
explain the lower relative share of hospital
costs in the French study compared to those
in previous reports. The French study (41)
estimated the average yearly cost of treating
PD in France at $5,129, which, if extrapo-
lated to the 80,000 PD cases estimated for
France, would yield a total annual cost of
$411 million to the healthcare system in gen-
eral. Again, the other personal indirect costs
and productivity losses were not estimated.
Another study, from Germany (40),
retrospectively assessed the medical costs only
of PD over a period of 3 months. The mean
3-month medical cost was $4,410 (1999 U.S.
dollars), which, when extrapolated to an
annual basis, is $17,642 (annual range was
$182–$121,835). Substantial variation was
identiﬁed in the cost of treatment with drugs,
which depended directly on the degree of
motor ﬂuctuations presented by the patient.
This same German study cited data from
the Organisation for Economic Co-operation
and Development (OECD), reported in 1996,
on drug expenses for several countries, includ-
ing the United States, in which $342 million
(1999 U.S. dollars) was reportedly spent.
For purposes of summary and compari-
son, selected results of the United States,
German, and French population studies are
presented in Table 3. All data in the table are
inflated to 1999 U.S. dollars, and extrapo-
lated to an annual basis. 
Other sources of information were located
on the World Wide Web, including the
Parkinson’s Action Network, That organiza-
tion includes a number of cost estimates for
PD in the United States, although there are
no real, retrievable sources for the data cited.
It is claimed that according to testimony
before the U.S. Senate Committee on Aging,
PD costs the United States an estimated $25
billion (1999 dollars) per year. These costs are
reported to be spread among afflicted fami-
lies, health and disability benefit providers,
Supplemental Security Income (SSI), Social
Security Death Index (SSDI), Medicare, and
Medicaid (44). A number of further claims
are made (all in 1999 U.S. dollars). These
include the following:
• L-Dopa and related drugs run
$1,000–$6,000 per year, per patient. For
the estimated 400,000–600,000 PD
patients in the United States, these costs
range from $400 million to $3.6 billion
per year.
• Ongoing care requirements include visits
to neurologists, various physical therapies,
and often treatment for depression.
Typical early-stage annual medical cost
per patient is $2,000–$7,000. The care
costs in advanced cases are higher. For the
PD patient numbers above, these costs
range from $800 million to $4.2 billion
per year.
• Treatment and hospitalization for PD-
caused falls can run $40,000 or more per
patient. According to W. Koller of the
University of Kansas, an estimated 38%
of PD sufferers do fall, and 13% fall more
than once a week (43). In total, these
costs range from $6.1 billion to $9.1 bil-
lion per year.
• According to R. Kurlan of the University
of Rochester, 31% of PD sufferers who
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Table 3. Direct and indirect medical costs per patient due to Parkinson’s disease in three countries.a
Germany (40) United States (35) France (41)
Care and nursing $4,788b $2,778c $1,886d
Drug therapy $5,360e $1,609 $1,180f
Inpatient hospital care $4,475g $16,555h $2,137i
Outpatient care $135j $1,259 —
Other expenses $2,914k $703l $262m
Total medical cost $17,642n $22,914 $5,465
Annual lost lifetime earnings $87,460o 4.8 sick days per 6-month period
aAll data in U.S. dollars. bBased on 3-month cost of $920 (1995 U.S. dollars). cIncludes cost of visits to physicians, other medical
providers, and home health visits by physicians and other healthcare providers. dBased on 6-month medical and ancillary care costs of
152 euros (EUR) and 662 EUR. eBased on 3-month cost of $1,030 (1995 U.S. dollars). fBased on 6-month cost of 509 EUR. gBased on 3-
month cost of $860 (1995 U.S. dollars). hIncludes cost of visits to hospitals, hospital physicians, and emergency room. iBased on 6-
month cost of 922 EUR. jBased on 3-month cost of $26 (1995 U.S. dollars). kBased on 3-month cost of $560 (1995 U.S. dollars).
lIncludes cost of nondurable and durable goods and visual-medical and dental visits. mConsists of medical transportation cost of 113
EUR, over a 6-month period. nBased on 3-month medical cost of $3,390 (1995 U.S. dollars). oThe annual lifetime lost earnings per per-
son in the German study is transferred from a study of Alzheimer patients that calculated annual lost lifetime earnings of approxi-
mately $50,380 (U.S. dollars) per person over all individuals diagnosed with the disease in 1991 (40).Muir and Zegarac
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are employed will have to leave their jobs
within a year (43). Disability income sub-
sidies can run $30,000 or more annually.
In total, these costs range from $3.7
billion to $5.6 billion per year.
• As the disease progresses, substantial dis-
ability (inability to maintain balance, walk,
speak, or move) requires assisted living or
nursing home care, which can exceed
$100,000 per patient annually. Assuming
just 5% of patients become totally dis-
abled, these costs can range from $2 billion
to $3 billion per year. If the number is
10%, the costs could range from $4 billion
to $6 billion per year. It is apparent that
these costs can balloon substantially if the
actual rate of disability is higher.
• Adding up the costs calculated above,
over the 400,000–600,000 PD patients
estimated for the United States amounts
to $13 billion to $28.5 billion per year.
That estimate may be low, depending on
the actual rate of disability that becomes
prevalent, as noted in the previous point.
Neurodevelopmental Effects and
Hypothyroidism
General results. Recent reports have pointed
out a number of issues and vital statistics
related to a reported epidemic of developmen-
tal, learning, and behavioral disabilities evident
among children in both Canada and the
United States and the possible contribution of
neurotoxic environmental contaminants to
those problems, with the actions of antithyroid
agents and hypothyroidism as one suggested
mechanism. These issues reﬂect concerns and
hypotheses raised in earlier reports and studies
in the scientiﬁc literature (1–6,38). 
Hypothyroidism can refer to a condition
in which the thyroid hormone available in tis-
sues is less than normal or optimal, all the
way down to its near or complete absence
(44). Hypothyroidism can develop from
genetic and autoimmune disease, can be med-
ically induced (iatrogenic) as in the treatment
of hyperthyroidism and thyroid cancer, or
can be due to thyroid dysfunction associated
with various environmental chemical and
physical agents, such as the radiation poison-
ing due to the Chernobyl event (45).
Thyroid hormones (THs) are essential for
normal growth and skeletal maturation.
Although THs are essential throughout life for
normal functioning of the central nervous sys-
tem (CNS), they are especially needed during
the fetal and neonatal periods for normal neu-
rodevelopment to occur (46). During these
periods, the CNS needs THs for its develop-
ment. THs (mainly T3) are needed for several
neurodevelopmental processes, and it func-
tions by regulating important brain genes.
The THs needs, effects, and functions are reg-
ulated at different places and times in the
brain, and THs play essential roles in brain
development and in the development and
regulation of neurotransmitter systems (47).
It is evident that the fetus is highly vul-
nerable to any insult to the thyroid system;
any thyroid deficiency (or excess) may pro-
duce irreversible, profound, more specific,
and possibly lasting brain and CNS effects,
depending on timing and degree of aberra-
tion. If THs are lacking for a long period,
extensive brain damage will occur. If they are
lacking for a brief time, then the effects will
be selective and speciﬁc for the region of the
brain that needs them at the time of defi-
ciency. More generally, if the developing
CNS is exposed to too little TH, the result
will be delayed and impaired CNS develop-
ment, damage, and possibly permanent
deﬁcits (46–49).
Maternal THs are thought to play the
predominant role in fetal development. The
human fetal thyroid system does not become
fully functional before term, and therefore,
the gestational TH gap needs to be met by
the maternal supply. Maternal thyroid defi-
ciencies can occur at different times and
severities during pregnancy, and thus may
contribute to different neurodevelopmental
impairments. These may include clinical or
subclinical maternal hypothyroidism
(screened for as elevated maternal thyroid-
stimulating hormone [TSH] in the second
trimester) or, as recently argued (50), first
trimester hypothyroxinemia (low-circulating
maternal T4, whether or not TSH is
increased) that may be more frequent and not
screened for. 
For present purposes, it is possible to dis-
tinguish among several manifestations of the
condition: as congenital hypothyroidism
(CH), as effects on the fetus other than CH,
and as acquired hypothyroidism in children or
adults. The thyroid gland is not essential to
life, but if it is defective or absent, as in chil-
dren with untreated CH, severe damage can
occur, including mental retardation and possi-
bly dwarfism (44). Even when screened and
treated, CH children can show reduced IQs
and other problems such as deﬁcits in atten-
tion, language, and memory skills (48,49).
Children with CH who are inadequately
treated have lower scores on intellectual,
achievement, and memory tests (46,48,
49,51). Moreover, even CH children who
were treated adequately and early performed
signiﬁcantly below expectation with respect to
intellectual functioning compared to controls
and showed significant declines in IQ with
age, signiﬁcantly poorer performance in visuo-
spatial, language, and fine motor areas, and
selective attention and memory deﬁcits (49).
Although delays in reading comprehension
and arithmetic skills evident at grade 3 were
caught up by grade 6, their teachers reported
that CH children were not performing as well
as controls in the classroom and demonstrated
difﬁculty with more complex subjects such as
science and social studies (48,49). The prob-
lem stems from the delay before treatment
takes effect, and the inability of the maternal
TH supply to fully compensate for the fetal
deﬁciency, which results in effects in utero and
late gestation.
Historically, mothers who were severely
hypothyroid gave birth to children who were
likewise hypothyroid from birth and were
born dwarfed, severely retarded, and with var-
ious deformities, and were called cretins (44).
Mothers who experience preterm birth have
children who lost the maternal TH supply
before their own fetal thyroid was competent
to fully supply their needs. These children,
too, suffer deficits, although milder ones,
depending on the extent of prematurity. Also,
premature infants sometimes have a transient
decrease in levels of THs following birth
(hypothyroxinemia); this has been associated
with a 5-fold increase in cerebral palsy at 2
years of age and an average decrease of 10 IQ
points compared with that in premature
infants who have normal thyroid levels (46).
More recently, it has been reported that
pregnant women with undiagnosed hypo-
thyroidism gave birth to children with quan-
tiﬁable deﬁcits in various neurologic measures
including IQ and measures of attention
(8,51–53). In other reports, subtle problems
of cognition, attention, and behavior are over-
represented in the offspring of mothers who
were hypothyroid during pregnancy (46,51).
Children, adolescents, and adults with
acquired hypothyroidism (AH) have poor
resistance to temperature, mental and physi-
cal slowing, slow metabolism, husky and slow
voice, slow mentation, poor memory, and
sometimes severe mental symptoms, espe-
cially depression (44). Adverse behavioral
reactions may occur, and learning problems
may persist, in juveniles treated for AH (54).
Least favorable outcomes occur in those with
more severe AH at diagnosis, and more favor-
able outcomes are seen in cases where euthy-
roidism is achieved more slowly. Critical
issues in treatment include possible abnormal
responses and resistance to TH. In the
elderly, AH may advance aging and create
additional memory problems.
Economic and societal costs—general. No
studies were found for this review that were
designed to estimate the economic, ﬁnancial,
or social costs of neurodevelopmental effects
and hypothyroidism. However, we did find
reports of widespread developmental brain
disorders that exist clinically and that are
possibly associated with hypothyroidism,
which is endemic. These effects have very
important public health implications and
whatever the cause, very substantial andSocietal costs of exposure to toxic substances
numerous but undocumented costs to health
care, education, public assistance, and effects
on society at large. 
The following statistics on public health
in the United States, which involve societal
costs, were reported in a study by the Greater
Boston Physicians for Social Responsibility
titled “In Harm’s Way: Toxic Threats to
Child Development” (8).
• It is estimated that nearly 12 million chil-
dren (17%) in the United States under 18
years of age suffer from one or more
learning, developmental, or behavioral
disabilities. Other reports put the total at
20 million or more (55).
• According to conservative estimates,
ADHD affects 3–6% of all school chil-
dren, although recent evidence suggests
the prevalence may be as high as 17%.
The number of children taking the drug
Ritalin for this disorder has roughly dou-
bled every 4–7 years since 1971 to reach
its current estimate of about 1.5 million.
The real total may be 8 million.
• Learning disabilities alone may affect
approximately 5–10% of children in
public schools.
• The number of children enrolled in spe-
cial education programs and classified
with learning disabilities increased 191%
from 1977 to 1994.
• Approximately 1% of all children are
mentally retarded.
• The incidence of autism may be as high as
2 per 1000 children. One study of the
prevelance of autism between 1966 and
1997 showed a doubling of rates over that
time span. Within the State of California,
the number of children entered into the
autism registry increased 210% between
1987 and 1998 (compared to a 60% rise
in population). Other studies report
worldwide increases of 3.8% per year and
total prevalence estimates as high as
400,000 in the United States (55).
• Children with these disorders are at sub-
stantial risk for school and workplace fail-
ure, drug abuse, delinquency, crime,
violence and mental illness.
With respect to Canada, a recent publica-
tion of the Canadian Institute of Child
Health titled “The Health of Canada’s
Children: ACICH Profile,” reported some
similar findings (9). These findings include
the following:
• Specific data regarding the documented
prevalence of neurobehavioral effects,
such as ADHD and learning disabilities
were presented as a question mark in the
report; however, it was stated that these
conditions “. . . affect a large proportion
of children.”
• It was reported that approximately
10–12% of all children have some
degree of cognitive deficits and learning
disabilities. One child in 10 received
some form of remedial education during
1995 and 1996. Of these children, 51%
had learning disabilities.
• According to a 1994–1995 survey of par-
ents, there was a high prevalence of hyper-
activity symptoms among children 8–11
years of age, with male children more
likely to have such symptoms than
females. The reported prevalence, of a
variety of symptoms (e.g., cannot concen-
trate, cannot pay attention, distractible,
impulsive, restless, hyperactive, fidgets),
ranged from 48 to 60% for boys, and
from 30 to 49% for girls.
• The same survey reported a substantial
proportion of these children have behav-
ioral problems, with a propensity to
aggression, violence, and destructive acts. 
• Children with hyperactivity and ADHD
are commonly administered the medica-
tion Ritalin. The number of Ritalin pills
dispensed in Canada more than doubled,
from 26.8 million to 56.2 million, from
1994 to 1998. 
• Although the majority of children from
birth to 3 years of age experienced normal
or advanced motor and social develop-
ment relative to their peers, about 14%
experienced delayed development.
• The overall state of diagnosis of disabili-
ties in children was also labeled with a
question mark.
For the Canadian context, other recent
reports in the media (56) are based mostly on
anecdotal information or information cited
from the Centre for Studies of Children at
Risk and from the U.S. Surgeon General’s
Report on Mental Health, 1999. These
reports support the more detailed data on
prevalence and incidence contained in the
U.S. study cited above but in some instances
(e.g., autism) suggest that the data may be
underestimates. 
These media sources report the following
data:
• There are an estimated 3,000–5,000 chil-
dren with autism in Ontario, and that
prevalence among children is two to five
cases per 10,000 individuals, 4–5 times
more males than females.
• An estimated 5% of the child population
has attention deficit disorder, but less
than 2% is being treated by medication
(usually Ritalin).
• One Ontario Health Study (57) found
that the prevalence of ADHD was 9% in
boys and 3% in girls; other estimates are
that prevalence of ADHD is 3–5% of
school-age children and the male to
female ratio ranges from 4:1 to 9:1 (55).
• Aggressive behavior and propensity to vio-
lence appear to have increased over the
last decade, with reported rates of 6–16%
in males, and 2–9 % in females.
• Other disorders have been reported, such
as depression, anxiety, and oppositional
defiant disorder, some of which persist
into adulthood, and a substantial number
of individuals continue to suffer from
them.
• According to other reported estimates, the
prevalence of these disorders is much
higher in recent reports, testimony, and
study.
Economic costs—case study. For this
review we did not ﬁnd any published, system-
atic, and comprehensive studies on the ﬁnan-
cial, economic, and social costs of
neurodevelopmental disorders and potentially
related hypothyroidism for either Canada or
the United States. To provide some back-
ground, we tried to gather partial data on spe-
cific costs incurred by various parties, or
estimates of what the costs might be, based
on data, reasonable assumptions, and extrap-
olation. In some cases, the costs are paid by
governments and in other cases by families or
medical insurance providers. We found the
following:
Canada and Ontario.
• The pharmaceutical product Synthoid,
indicated for the treatment of hypothy-
roidism, was the most frequently dis-
pensed medication in Canada in 1999,
totaling just over 5 million prescriptions.
Prescriptions for this medication grew by
14% in 1999. Another drug, Eltroxin, for
hypothyroidism was 19 out of the top 20
dispensed drugs, totaling 1.8 million pre-
scriptions. Reasons given for the increases
were higher prevalence and earlier treat-
ment to avoid progression of the disease.
No estimate of the costs involved was
available (33).
• According to the Ontario Ministry of
Health, hospital treatment for hypothy-
roidism cost an average of $591,000 per
year over the 1996–1998 period. This
amounted to about $3,400 per case. In
addition, in the reporting period
1998–1999, OHIP paid doctors almost
$8.1 million for treating patients who had
hypothyroidism (34).
• Ontario Ministry of Health data indicate
that almost $1 million per year over the
1996–1998 period was the average cost
for hospital treatment of patients with
ADHD, autism, dyslexia and other
assorted learning disorders. The majority
of the cost was for ADHD, followed by
autism and learning disorders; the cost for
dyslexia was just over 1%. In addition,
almost $8.4 million was the cost for the
1998–1999 reporting period for doctor
treatments of these same diagnoses.
ADHD accounted for almost 75%,
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dyslexia less than 25%, and autism about
8% of these doctor costs (34).
• According to the Ontario Ministry of
Education, some 188,000 students in
Ontario need special education. The min-
istry has budgeted $1,218 million or
about $6,477 per student for the year
1999–2000 (58). The Hamilton–
Wentworth District School Board spent
about $7,660 per student for the
1999–2000 school year; the board
received only the lower average from the
ministry, so the board had to make up the
shortfall by diverting funds from other
allocations (59).
• The issue of funding for special educa-
tion to meet the needs of autistic,
ADHD, and other learning-disabled chil-
dren is controversial, and arguments exist
that it is much underfunded or not
funded at all. For example, anecdotal evi-
dence indicates that it costs families
about $17,000 (and more) per year (in
1999 CDN dollars) for an autistic child;
this is not paid for by the healthcare sys-
tem in Ontario. Extrapolating to the esti-
mated 3,000–5,000 autistic children
amounts to $51 million to $85 million per
year as an estimated cost to the families. 
• According to the Ontario Ministry of
Correctional Services, adolescents with
learning disabilities are disproportionately
involved with the juvenile justice system.
According to the U.S. National Center
for State Courts and the Educational
Testing Service in 1997, 50% of juvenile
delinquents tested were found to have
undetected learning disabilities (60).
Assuming this percentage is similar in
Ontario, and using ministry-provided
data, the average annual cost for this 50%
is $473,289,790 for those in closed cus-
tody. A similar 50% of open custody resi-
dents costs another $11,255,396 (61).
• As an estimate, if the 56.2 million Ritalin
pills sold in Canada in 1998 cost 89 cents
each (10 mg) for brand name product
(62), that would amount to about $50
million (in 1999 dollars) per year.
United States (62).
• Using the estimate that nearly 12 million
children in the United States suffer from
some form of learning, developmental, or
behavioral disability, and the special edu-
cation funding per student budgeted by
the Ontario Ministry of Education, and
the Hamilton–Wentworth District
School Board ($6,477 and $7,660,
respectively) results in a comparable cost
to the United States of between almost
$78 billion and $92 billion per year (1999
CDN dollars). There are other estimates
that the total population of people with
developmental brain disorders in the
United States is over 20 million (55).
This number of cases would put the costs
at $130 billion–$153 billion per year.
• If the estimated 1.5 million children in the
United States are prescribed the Ritalin
and each child takes 4 pills per day for 365
days per year, that would total 2.190 bil-
lion pills a year. If each pill costs 89 cents,
as noted above, the cost would be $1.95
billion per year. Other estimates of Ritalin
use may approach 8 million children,
which is 5.3 times higher than our example
above and at the example price, amounts
to $10.3 billion. This hypothetical example
costs $25 per week per child. Anecdotal
estimates put drug costs at up to $50 per
week. On the other hand, this example
does not account for generic drug prices
and may overestimate the amount of the
drug taken. However, the example can be
modiﬁed with more accurate information.
• Considering that the population of the
United States is roughly (in round num-
bers) 30 times that of Ontario and assum-
ing the same autism prevalence estimates
of 3,000–5,000 in Ontario, extrapolates
to about 90,000–150,000 cases in the
United States. Using the same cost of
$17,000 per child per year amounts to
$1.53 billion–$2.55 billion CDN dollars
per year [but see (63)].
• If the estimate that autism spectrum dis-
orders affect 400,000 people in the
United States is more realistic, the costs
would be $6.8 billion per year. This esti-
mate of total prevalence has implications
for the estimate reported for Ontario. If
the prevalence in the two locations is
really approximately equal, using the rela-
tive size factor of 30 implies a total preva-
lence in Ontario of about 13,300, and a
cost of $226 million per year in Ontario.
• There are also anecdotal reports of other
drugs such as Prozac being dispensed to
children who have the disorders consid-
ered here. No estimates of usage were
available; however, one estimate (62), for
the brand name product, 20 mg dose, was
$2.40 per pill.
Neurodevelopmental Effects and
Intelligence Quotient
General results. There is much concern in the
literature that exposure to neurotoxic agents
in the environment can produce deficits in
certain measures of cognitive performance,
such as IQ, as one effect that is easy to quan-
tify compared to the many other neurobehav-
ioral effects seen in studies (21,38,39). This
has negative implications for the individuals
involved but also less well-appreciated long-
term consequences for the population and
society as a whole. 
It should be obvious that the quality of
human capital must always be of paramount
concern in any society, and in an era charac-
terized as the Information Age, where knowl-
edge and high technology are the currency of
the day, it needs to be of central importance.
Chemical or physical agents that can result in
the “dumbing down” of the population are
like nails in the economic cofﬁn. 
All knowledge, all technology and manu-
factured capital, all forms of social and pro-
ductive organization, all sustainable
environments and natural capital stocks, and
all true economic innovation and progress—
all growth and development—are tributary
products of human creativity and praxis.
Surely, the ultimate pollution is the chemical
contamination of the brain, mind, and intelli-
gence that form the source of our good for-
tune. This pollution not only affects the
educational attainment, economic perfor-
mance, and income of the individual, but it
also has an impact on the dynamic perfor-
mance of the economy as a whole through its
effect on the quality of the human capital
stock, and in turn, on society’s potential pro-
duction possibilities, the rate of technical
progress, and the overall productivity. 
Impaired child development has a number
of negative outcomes and economic burdens.
Lowered IQ, as measured by standardized
tests, has a documented relationship with eco-
nomic outcomes such as lifetime earnings. A
number of studies (13,17,18) link small decre-
ments in IQ around the mean to lower wages,
and in turn, earnings; some well-established
empirical relationships exist between IQ and
several determinants of wages and earnings, as
well as earnings directly.
More generally, although the IQ effects
may be the easiest to quantify, they may not
be the most serious in terms of life and career
outcomes. Toxicants that put the nervous
system at risk also affect executive function,
for example, planning, organization, and ini-
tiating ideas; they may also induce problems
with attention, for example, distractibility,
impulsive behavior, inability to handle stress
and disappointments, and to delay gratifica-
tion. These effects would constitute to many
a much more serious effect of toxicants with
respect to success in school and in life, and
with respect to possible antisocial behavior
(64). This has obvious negative implications
for excellence in the development of leaders
such as chief executive ofﬁcers, scientists, and
management and administration ofﬁcials and
thus may impact both our economy and
society (64).
As noted in the section above, evidence
indicates that hypothyroidism in pregnancy
negatively affects babies’ intelligence, as mea-
sured by IQ, the normal distribution of
which is shifted toward a higher percentage ofSocietal costs of exposure to toxic substances
the population scoring lower, compared to
that of controls (8,45,46,49). There is also
evidence that exposure to some toxic sub-
stances, at some life stage, results in lower IQ
in the affected individual (17,65). 
In general, lower population-average IQ
shifts the distribution and increases the num-
ber of individuals who have low IQs (e.g.,
below 70 or 85) and who thus may be classi-
ﬁed as retarded. It also decreases the number
of gifted and exceptionally gifted individuals
with high IQs (above 130), who may be the
geniuses and prodigies of the immediate
future. For example, if the average is lowered
by 5 IQ points (in a normal distribution with
a mean of 100, and standard deviation of 15),
the number that score below 70 increases by a
factor of 2, and the number that score above
130 decreases by a factor of 2.5 (38,39). The
increase in the lower IQ proportion creates
burdens on society in the form of a variety of
social problems and costs (38,39,65). The
loss of gifted people also has its own set of
burdens and costs to society, which appear in
many forms, including lost potential, excel-
lence, and greatness. 
Schettler et al. (8) provide some specific
numbers for this scenario, for a population of
260 million. The 5-point IQ reduction in the
population mean, from 100 to 95, increases
the number of people below 70 from 6 mil-
lion to 9.4 million. The same decrease
reduces the number of gifted from 6 million
to 2.4 million. This would qualify as a dumb-
ing down of the population—not a happy
prospect for society.
Such a populationwide effect is more than
a hypothetical possibility. The whole popula-
tion has been and continues to be exposed to a
wide variety of environmental agents such as
lead, other heavy metals; polychlorinated
biphenyls; dioxins; pesticides; flame retar-
dants; surfactants; hormones; cleansers; sol-
vents; plasticizers; dyes; numerous industrial,
food, and water additives; pharmaceuticals;
radiation; and other substances, many of
which have known toxic and neurotoxic prop-
erties, and endocrine-disrupting properties. 
Given this universal exposure, the speciﬁc
effects on individuals or the distribution of
cases, would depend on susceptibility, and
although exposure probably affects children
more (as fetuses, children/adolescents/juve-
niles), adults are not immune. The effects
may appear as multiaspect syndromes or as
seemingly random events, and the environ-
mental hazard(s) or causes may be quite
unfindable by traditional methods because
there is no unexposed group to act as controls
and no systematic heterogeneity or diversity
of exposure, and because the existing preva-
lence of suspect effects is already high, mak-
ing rigorous statistical detection even more
difﬁcult (66). A populationwide effect such as
IQ loss could become manifest without our
knowing it for all these reasons, and because
of time lags, multifactorial etiology, geo-
graphic scale and differences, and changing
test standards—and because we are not really
measuring for it. 
We measure IQ in children infrequently,
with spotty coverage, and almost never mea-
sure beyond young adulthood. Ultimately,
over time, the cohorts most affected add up
to the bulk of the population as a whole. This
situation is at the root of the issue and one
reason this case study was chosen. It is also a
reason why efforts should be made to esti-
mate the number of children and adults actu-
ally affected, so that the cost estimates
presented here for populationwide IQ losses
and shifts in the distribution of IQ can be
proportioned and hypotheses tested. Note
that the impacts estimated by Schwartz (17)
and Salkever (18) in the context of lead expo-
sure, which are adapted in the analysis that
appears below, are based on the cohort of 6-
year-old children as the number of children
actually affected annually and not the entire
population. Therefore these impacts are
already fully proportioned as extensions of
these works but subject to their limitations.
We did not find reference to any study
reporting any populationwide IQ loss,
although the “In Harm’s Way” study (8), and
the comparable Canadian report (9) surely
indicate that a big problem exists with the
neurodevelopmental health of children, and
with adult health as well, even if the IQ
implications are not measured or reported.
Moreover, these studies are not the first to
identify declines in human quality involving a
number of aspects, including data showing
lowered test scores on Standardized Aptitude
Tests across the United States. This decline
was attributed to environmental stresses,
including toxic substances (67). 
More generally, it is not evident that any
such IQ study has ever been conducted or
that such an attributable decline could be eas-
ily measured, and with statistical power. It
does not seem that we are set up to do the
measurement. The absence of evidence is not
evidence of absence.
Economic costs—case study. The method-
ology and estimation of the societal and eco-
nomic costs of changes in IQ have been well
developed in the context of reducing lead
exposure (13,18,68). These methods have
been used to evaluate the costs associated
with children born to mothers who smoked
during pregnancy. The results of these studies
will be reported here. They also will be
updated, adapted, extended, and used to
account for dynamic economic impacts, for
the purposes of the present project. As dis-
cussed above, however, note that because
many possible neurobehavioral effects can be
seen in studies, looking at IQ alone probably
seriously underestimates the costs to society
of these disorders.
Impacts on earnings. The seminal study by
Schwartz (17) extended the 1985 U.S.
Environmental Protection Agency report (13)
on the costs and beneﬁts of reducing lead in
gasoline. The study by Schwartz provides a
useful framework on the basis of a synthesis
of various empirical studies on the contribu-
tion of IQ, schooling, and labor-force partici-
pation in the determination of earnings. It
may be used as a prototypical analysis of a
neurotoxic agent that results in a decline in
IQ and that may also result in other cognitive
deficits related to executive function, atten-
tion, hyperactivity, hearing, reading ability,
language, visual perception, ﬁne motor skills,
school performance, and ultimately, partici-
pation in the labor force, lifetime earnings
and success in life (38,39,65). Again, as dis-
cussed above, these latter deﬁcits may be even
more important than the IQ deficit in ulti-
mate school performance and the likelihood
of leading a “good life” (38).
Schwartz (17) reports that the decline in
earnings equals the net present value of life-
time earnings times the sum of two percentage
changes: the percentage decrease in earnings
for people who do work, plus the percentage
decrease in the probability of working at all
(the participation rate). The second change
results from the impact of neurodevelopment
effects and IQ on schooling and, in turn, on
participation. The estimates of these relation-
ships are derived by synthesizing empirical
estimates of others that are based on linear
functions, and therefore can be criticized on
the grounds that linearity may not be correct.
However, the exploration of this issue is
beyond the scope of the present report. 
The earnings losses do not account for
possible higher economic penalties per IQ
point lost at the high end of the earnings scale
than at the low end. Schwartz applies this
decline to each child for the cohort turning 6
years of age each year. The cohort of 6-year-
old children was chosen because the IQ
studies are generally done in school-age chil-
dren and infant studies will not necessarily
show the same correlation with earnings (68).
Below, the original estimates of earnings
losses, as reported in the reviewed studies, are
presented. These first estimates are reported
in their original units (1987 U.S. dollars) for
illustrative purposes and because simply
adjusting these for inﬂation to today will not
necessarily reflect accurate changes in actual
earnings over such a long period and they
may be misleading. Later, these estimates will
be updated to reflect changes in base-year
dollar values, updated survey estimates of
actual earnings, changes in expected lifetime
earnings, and changes in the chosen cohort. It
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is these later estimates that are the most
relevant for our current purposes. 
Schwartz calculated a 1.763% loss in earn-
ings per 1-point IQ decrement, for males and
females combined. Applied to his 1987-dollar
estimate of the present value (PV) of lifetime
earnings of $301,000 yielded a loss per child,
per IQ point, of $5,307. The Schwartz PV is
calculated for a child of 6 years old, starting
work at age 15, working to age 65, with the
calculated earnings stream growing at 1% real
per year as wage increases, and discounted at a
real rate of 5% back to age 6. Because the size
of his cohort of 6-year-old children was 3.9
million and we are considering the ultimate
effects on the whole population, this yields a
loss in earnings of almost $20.7 billion per
year, per IQ point. The earnings loss is an
annual one because each year the cohort of
6-year-old children is turned over and
replaced in similar size and the loss must be
calculated again for the new cohort (68).
For illustrative purposes of the current
study, the average IQ loss chosen by the IJC
SAB Working Group was 5 IQ points. This
choice is plausible because it is consistent
with relevant effects and deﬁcits reported else-
where (38,45,46,65,67–69). This means that
the total income loss per year due to a 5-point
IQ decrement, calculated using Schwartz’s
results, amounts to almost $104 billion per
year in 1987 U.S. dollars.
In a subsequent study, Salkever (18), used
Schwartz’s basic approach with minor exten-
sions to explicitly estimate the direct effects of
IQ on educational attainment and participa-
tion. In addition, on the basis of more up-to-
date data, Salkever developed new estimates
for the effects of IQ on earnings, of schooling
on earnings, and of schooling on participa-
tion. He also reports separate estimates for
males and females.
Table 4 displays the estimated percent
earnings loss per IQ point decrease, as reported
in the Schwartz and Salkever studies. Salkever’s
estimates are generally higher with one excep-
tion, but especially so for females. In 1987 dol-
lars, Salkever’s estimates of earnings loss per IQ
point is $6,303 per male, and $10,929 per
female (18). However, these estimates are
based on expected lifetime earnings calculated
as combined for males and females for 1987
U.S. dollars ($301,000). Table 5 presents, for
comparison, the earnings loss per IQ point
from the two studies. Using Salkever’s updates
provides a substantial increase in the annual
earnings loss per IQ point decrease, from
$20.7 billion to $33.4 billion per IQ point
decrease, or for the 5-point decrease in the
present review, from $103.4 billion per year to
$167 billion per year, all in 1987 dollars,
earnings levels, and cohort size.
The next sections provide an update and
addition to the analysis presented above using
the most recently available data on earnings
and demographics. We also include estimates
for the Canadian context (Tables 6, 7).
Table 6 uses recent data on earnings in
the United States, surveyed in 1998 for males
and females separately, to update to 1999
dollars the various estimates of per-person
earnings losses per IQ point decrease, accord-
ing to the methods of Schwartz and Salkever.
It provides a similar estimate in 1999 dollars
for Canada, using Canadian earnings data as
reported in the 1996 Census (70) and
Salkever’s earnings loss estimates. All these
estimates are close approximations to a recent
hypothetical example of $10,000 expected
value of lifetime earnings loss per IQ point
decrease used in the context of the children of
mothers who smoked during pregnancy (65).
In this update, the average Canadian
earnings, in 1999 dollars, of males and
females participating in the labor force were
$33,077 and $20,418, respectively (71).
Many adults do not participate in the work-
force or do not participate for all their poten-
tial working years. The largest such group
consists of women who remain at home
doing housework and rearing children.
As in Schwartz, we have assumed the
opportunity cost of nonparticipation in the
workforce to be half the value for employed
workers of the same sex. In 1996, there were
approximately 8 million male participants
(72) in the labor force and approximately 3
million male nonparticipants. In the case of
females, in 1996 there were approximately
6.8 million participants and 4.8 million
female nonparticipants (70).
Also as Schwartz does, we have assumed a
1% real-wage growth in the future from the
1995 distribution of income and have
updated his discount rate. We now use a real
discount rate of 3.5% in our calculations of
the net present value of lifetime earnings in
the Canadian update. This discount rate is
based on the October 2000, Government of
Canada 30-year real-return bond issue (73).
The updated U.S. estimates for 1999 use the
same 3.5% real discount rate. For Canada, the
expected lifetime earnings losses (1999 CDN
dollars) per IQ point decrease, per person, are
$14,838 for males and $14,594 for females.
As seen in Table 6, accounting for dif-
ferences between male and female earnings in
the United States reverses the earnings losses
Table 4. Percentage earnings loss per IQ point decrease from two studies.
Salkever (18)
Schwartz (17) Male Female
Direct + indirect effect on probability of participation –0.47 –0.215 –0.911
Direct + indirect effect on earnings –1.29 –1.879 –2.720
Total percentage effect –1.763 –2.094 –3.631
Table 6. Updated earnings loss per IQ point decrease, United States and Canada, in 1999 dollars.a
Salkever d,e Canadian updatef
Schwartzb,c Male Female Male Female
IQ direct + indirect effect on  $3,647 $1,756 $3,829 $1,523 $3,662
probability of participation
IQ direct + indirect effect on earnings $10,010 $15,342 $11,433 $13,315 $10,932
Total effect $13,680g $17,098 $15,262 $14,838 $14,594
aAll data in this table are inﬂated using the “All Items”component of the U.S. or Canada Consumer Price Index. bThe updated numbers
are based on the combined net present value (calculated using a real discount rate of 3.5%) of earnings for U.S. males and females for
1998. cThe earnings loss per IQ point is estimated by multiplying the predicted change in wages, according to Schwartz (17) by the
combined net present value of expected lifetime earnings. A combined net present value of earnings for U.S. males and females,
based on 1998 Bureau of Labor earnings data is $749,001. dThe updated numbers are based on the net present value (calculated using
a real discount rate of 3.5%) of earnings for U.S. males and females for 1998. eThe earnings loss per IQ point is estimated by multiply-
ing the predicted change in wages, according to Salkever (18), by the net present values (calculated using a real discount rate of 3.5%)
of expected lifetime earnings for males and females. The net present values of earnings for U.S. males and females at age 6, starting
work at age 15 and working to age 65, based on 1998 U.S. Bureau of Labor earnings and participation rate data, are $788,139 and
$405,746, respectively. fThe net present values of earnings for Canadian males and females have been multiplied by the percentage
earnings loss per IQ point decrease according to Salkever (18). The net present values (calculated using a real discount rate of 3.5%)
of earnings for Canadian males and females at age 6, starting work at age 15 and working to age 65 are $666,656 and $378,099,
respectively. gThe total effect under Schwartz was determined by multiplying the total percentage earnings loss (1.763%) by the com-
bined net present value of earnings for U.S. males and females surveyed in 1998. 
Table 5. Earnings loss per IQ point for cohort of 6-year-old children in the United States, 1987 dollars. 
Males Females Combined
Cohort population, mid-1980sa 1,992,900 1,907,100 3,900,000
Earnings loss, Schwartz (17) $10,576,320,300 $10,120,979,700 $20,697,300,000
Earnings loss, Salkever (18)b $12,561,248,700 $20,842,695,900 $33,403,944,600
aThe population ﬁgure for 6-year-old children in the United States in the mid-1980s was broken down by gender using the male and
female ratios for 6-year-old children in the United States in 1990. In 1990, the ratio was 51.1% males to 48.9% females. bEarnings
loss per IQ point was calculated by multiplying the earnings loss per IQ point by the number of persons within the cohort.Societal costs of exposure to toxic substances
of females compared to those of males
determined by using Schwartz’s estimate of
combined lifetime earnings, and Salkever’s
percent income losses in Table 4, as was done
previously and discussed above. That is, the
earlier estimate had females’ losses greater than
those of males, which is reversed in Table 6.
Table 7 presents the total expected life-
time earnings loss per year, presented here in
1999 dollars, based on 1998 dollar U.S. earn-
ings, and for the U.S. cohort of 6-year-old
children as it was reported in the 1998 census
(74,75). Table 7 shows that in the United
States, annual loss per IQ point decrease is
now estimated at approximately $55 billion
(1999 dollars) according to Schwartz, and
approximately $65 billion according to
Salkever; for a 5-point IQ decrease, these
losses are $275 billion and $326 billion,
respectively, per year.
For Canada, Table 7 provides the
estimates of earning losses per IQ point
decrease for the entire Canadian and Ontario
cohorts of 6-year-old children. The total
annual loss in Canada is $6 billion and in
Ontario it is approximately $2.3 billion. In
terms of the 5-point IQ decrease considered in
the current study, these losses are almost $30
billion and $11.5 billion per year, respectively.
Impacts on social costs. Weiss and co-
workers (28,65) point to the importance of
examining the extremes of distributions, such
as those for IQ in a population. For present
purposes, one particular set of social out-
comes with economic consequences related to
shifts in the mean of the IQ distribution is
highly relevant. These researchers refer to a
previous study that calculates the beneﬁts of a
3% rise in IQ scores (39,65). This example
could be looked at in the negative as the costs
of not achieving a 3% rise, or the costs of a
3% decline. These social outcomes and the
estimated impacts (percent increases of back-
ground) on their prevalence are presented in
Table 8. For this review we were not able to
identify or estimate economic costs usually
associated with the above outcomes in most
cases. However, sufficient data were located
in some cases to provide the following pre-
liminary estimate of associated costs:
• Burtraw (76) estimates the incremental
direct costs of low birth weight among
children from birth to age 15, for 1988 in
the United States (76). Because low birth-
weight rates do not change substantially
from year to year, these costs can be seen as
annual costs. In 1988 there were 271,000
low-birth-weight babies, and the incremen-
tal healthcare costs associated with those
babies as infants were $15,000 each, for a
total of $4 billion (1988 dollars). Updating
these costs from 1988 to 1999 dollars,
using the Medical Care component of the
U.S. Consumer Price Index, involves an
inﬂation factor of 1.81 (31), which would
bring the total to $7.24 billion. If low-
weight births increase by 12% for a decline
of 3 IQ points, the cost of this increase
would be $869 million. Other costs associ-
ated with low birth weight to age 15
totaled an additional $2.53 billion (1999
dollars), so the incremental cost would be
another $304 million, for a total of $1.17
billion. These costs would generally be
incurred every year.
• In Canada and in Ontario, in 1995–
1996 there were 21,602 and 8,728 low-
birth-weight babies, respectively (77,78).
If the healthcare costs at infancy in
Canada and Ontario are similar to the
U.S. costs, this amounts to $399 million
and $161 million (1988 CDN dollars),
respectively. Updating these costs to
1999 dollars, using the Health Care com-
ponent of the Canadian Consumer Price
Index, involves a factor of 1.32 (79),
which would bring the totals to $527
million and $213 million, respectively. If
the incidences of low birth weight
increase by 12%, then the respective costs
for Canada and Ontario are $63.24 mil-
lion and $25.56 million. Again, these
costs would be incurred every year.
• In Ontario, from 31 March 1996 to
31 March 1999, an average of 1,091,400
people were on welfare per year, and the
unweighted average beneﬁt level in 1997,
updated to 1999 Canadian dollars, was
$12,965 (32), yielding a total welfare cost
estimate of almost $14.15 billion per year.
If welfare recipients increase by 18%
because of a 3% decrease in average IQ
score, this cost, for Ontario only, is more
than $255 million per year.
• In 1996, the U.S. prison and jail popula-
tion reached a total of 1.7 million
persons, and the cost was $32.916 bil-
lion (1999 U.S. dollars) per year (80).
This was more than triple the population
of 1980 (80). If an average IQ decrease
of 3% implies a 25% increase in males
interviewed in jail, the cost increases to
$8.2 billion per year for male prisoners
only. The prison and jail populations in
the United States rose at a rate of 7% a
year from 1990 to 1996, as reported, and
may have continued at this rate of
increase since then. 
• Since data are available on the costs of
young offender services in Ontario, as
noted above (61), these data can be used
as an example estimate of one small part
of the whole cost. As noted above, the
cost of youth offender services in Ontario
in 1999–2000 was about $947 million
(CDN dollars) per year. If the number of
males interviewed in jail goes up by 25%,
the youth component would imply costs
of $237 million per year in Ontario alone.
Information and data on the other out-
comes were not available; however, some of
the costs would overlap, (e.g., welfare recipi-
ency, poverty rate, out-of-wedlock children,
and children without parents); other costs are
related to the earnings losses, costs of special
education, and costs from other cognitive dis-
orders described above.
Dynamic economic impacts on growth and
development. A consideration of the possible
dynamic impacts of changes in average IQ
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Table 7. Updated earnings loss per IQ point for cohort of 6-year-old children, United States, Canada, and Ontario.a
United Statesb Canadac Ontarioc
Maled,e Femaled,e Maled,e Femaled,e Maled,e Femaled,e
Cohort populationf 2,054 1,966 210.355 200.245 79.025 75.095
Earnings loss  $28,098,720g–$35,119,292h $26,894,880g–$30,005,092h $3,121,248 $2,922,376 $1,172,573 $1,095,936
aAll ﬁnancial data in this table are inﬂated using the “All Items” component of the U.S. or Canada Consumer Price Index. bU.S. updated total earnings loss per IQ point is provided above in 1999 U.S. dol-
lars. cCanada and Ontario total earnings loss per IQ point is provided above in 1999 Canadian dollars. dIn thousands. eTotal earnings loss per IQ point, under Schwartz (17), for combined males and females
in the cohort of 6-year-old children for all of the United States is $54,993,600,000 (1999 U.S. dollars). Under Salkever (18), the combined total for all of the United States is $65,124,384,000 (1999 U.S. dol-
lars). The combined total loss for all of Canada is $6,043,626,000 (1999 CDN dollars). The combined total loss for all of Ontario is $2,268,509,000 (1999 CDN dollars). fThe upper range in U.S. earnings loss
is based on the assumptions used by Salkever (18). gCohort for the United States is based on 1998 data, whereas the cohorts for Canada and Ontario are based on 1995 earnings data, reported in the 1996
Census. hThe lower range in U.S. earnings loss is based on the assumptions used by Schwartz (17).
Table 8. Increase in prevalence of selected social out-
comes due to a decline of 3 points in average population
IQ.
Estimate of 
Social outcome prevalence (%)
Poverty during ﬁrst three years of life +20
Bottom decile HOME scores +13
Out-of-wedlock births +15
Low-weight births +12
Welfare recipiency +18
Children without parents +20
High school dropouts +28
Males interviewed in jail +25
Poverty rate +25
HOME, home observation for measurement of the environment.Muir and Zegarac
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and in the extremes of the distribution of IQ
is essential, as it enters into fundamental
questions of the basic production process, the
quality of the various factors of production
(e.g., land, labor, capital, other), productivity
growth, and overall economic growth and
development. At this time, economic science
is unable to explain much of the observed
growth in output in terms of growth in the
conventional inputs (81). In fact, historically,
less than half the United States increase in
output, in productivity per capita, and in real
wages can be accounted for by, ﬁrst of all, the
increase in capital itself, and then, by the
increase in other factors (81,82).
That part of growth in output that cannot
be explained is referred to as the residual. This
residual was attributed to a general term noted
as technical change or technical progress,
which is itself composed of improvements in
the quality of the various forms of conven-
tional inputs—human labor, manufactured
capital, resources and natural capital stocks,
scientiﬁc and engineering advances, industrial
organization, management know-how, and
investments in human education and in
research and development, as well as a number
of other not otherwise measured sources of
efﬁciency and technical change.
All these sources of inputs to the produc-
tion process, and technical change, are some-
how downstream or tributary to the primary
input that comes from humans and their
intellectual and physical labors. Even the pri-
mary products of the land-base, such as agri-
culture, forestry, fishing, and mining, are
tributary to the human form of capital.
It is elementary economics that all
factors of production act together, each
needing the others to increase the potential
output or production possibilities. Each fac-
tor has a quantity and quality aspect that
together and separately fill the role of con-
tributing to potential output and to various
configurations of the production possibility
frontier. It is called potential or possibility
because in the real world many things hap-
pen that can increase or decrease the share of
the maximum potential or possible output
actually realized. 
Although it is evident that manufactured
capital can be substituted substantially for
human and other forms of capital, this is not
likely to be an unlimited process. There is an
inherent complement between human capi-
tal, its quality, and the other forms of inputs,
and the ultimate production of output.
It seems reasonable to conjecture, that if
the quality of human capital is degraded
through the introduction of cognitive and
behavioral deficits such as decreased IQ and
competence, learning disorders, inattention,
and emotional and social reactivity, this will
ultimately have a negative impact on the scale
of potential output that is possible and the
share of this possible output that is actually
realized. In effect, this is creating a limita-
tional factor. This will happen because all of
the sources of production inputs and techni-
cal changes thus far identiﬁed are dependent
in some fundamental way on the quality of
the human capital and labor and creativity
that form the systems that design, produce,
install, operate, maintain, and improve them.
While lowering the mean IQ for an indi-
vidual has, perhaps arguably, small economic
changes overall except perhaps for that indi-
vidual, lowering IQ for the population as a
whole and changing the content of the
extremes of the distribution of IQ is another
matter. As noted above the universal exposure
of the entire population to a large number of
toxic substances makes such population
effects a real possibility.
As we have seen, increasing the number of
individuals who have low IQs, for example,
below 70, acts as a drag on society through a
wide variety of social and economic costs and
impacts, including the propensity to violence
touched on above. However, decreasing the
number of individuals with the highest IQs
undermines the source of the greatest human
potential, genius, creativity, innovation, and
achievement (intellectually, artistically, and in
countless other ways). It truly reflects the
degradation of the quality of human capital
and will be the most felt impact in the eco-
nomic, technological, and cultural spheres.
It is this aspect, in particular, of the dumb-
ing down of the population that cannot be
dismissed as a “small change,” still falling in
the so-called normal range—which is a com-
ment sometimes heard about the conse-
quences of the loss of a few IQ points in the
average individual. It is in fact, from an eco-
nomic perspective, a form of negative tech-
nical change—technologic retrogression
instead of progress. 
Estimates of the earnings losses to individ-
uals and cohorts due to decreases in IQ (and
other disease states) have been presented
above. These losses are examples of how the
actual realized share of the potential or possi-
ble output is less than the maximum, or less
than the production possibility frontier (PPF). 
In criticism, one could argue that scaling
these individual losses in IQ, which would
reasonably put the affected individual at a
competitive disadvantage in the workplace
and result in income losses, up to the popula-
tion level, is questionable. If everyone loses
5 IQ points, for example, then no one has
been placed at a competitive disadvantage.
This of course assumes immediately that it is
only the relative IQ that matters, not the
absolute level, implying there is no logical
limit to how low the average IQ could go and
still have no impact on individuals (or on the
economy and society). Moreover, this point
fails to consider that the population average
IQ is a summary statistic, a measure of cen-
tral tendency derived from the individual
measures which in reality are distributed (in
our case we have assumed normally) around
the central tendencies (which are the same in
a normal distribution). It confuses the popu-
lation average with the individual scores,
which are expected to show a variation.
Therefore, if the average dropped by 5
points, individuals would be expected to
have drops that vary above and below the
average. For example, in a population of
three, drops of 1, 5, and 9 points would yield
an average drop of 5, but the individuals
would be differentially affected in terms of
any competitive disadvantage. 
This point of criticism also fails to recog-
nize that a lower population average IQ
would be expected to have a global form of
competitive disadvantage for that society,
affecting all individuals more or less, regard-
less of their individual IQs and its ranking in
terms of the population. That is, it is reason-
able to expect that lowering the population
IQ on average would have a negative overall
economic impact internally, and also with
respect to the competitive advantage
compared to trading partners.
More generally, the following analysis is
not so much concerned with scaling up indi-
vidual losses to the population level, but with
the possible impacts and losses on a macro
scale due to the shifts in the entire distribu-
tion of IQ including the tails, the accompa-
nying changes in the intellectual quality of
human capital, and their potential contribu-
tions to the dynamics of production, techni-
cal progress, and economic and social
well-being. How that can be estimated is not
settled, but we explore it here.
The dynamics of interest here relate to
changes in the determination of potential
output, or outward shifts in the production
possibility frontier. We would like to know
how decreases in average IQ, and in the
extremes of the distribution of IQ, interact in
the economic process to induce an effect anal-
ogous to negative technical change or to
dampen the growth in output and productiv-
ity, both real and potential, that would other-
wise result. Put another way, the PPF is really
being shifted inward relative to where it
would be in the absence of the proposed
impacts on human intellectual quality.
The unfortunate fact is that economic
science cannot yet, and probably never will be
able to—for a variety of data, measurement,
and statistical problems—empirically measure
and explain quantitatively the various contri-
butions of all these factors, positives and nega-
tives, to the processes of technical change,
economic growth, and development (80). SoSocietal costs of exposure to toxic substances
we are left to making hypotheses and to
examining the economic performance measures
available and relevant to the issue at hand. The
stakes are very large, as can be seen by examin-
ing the nature of the growth and development
and the productivity growth in the recent past
of the United States and Canada.
To illustrate the size of the economic
growth and productivity growth that is the
most relevant and simplest for the purposes of
this review, we can examine real (adjusted for
inﬂation) GDP and real GDP per man hour
worked. In terms of real GDP, consider the
following:
• In the United States between 1990 and
1998, the growth in real (1992 dollars)
GDP in absolute dollars averaged
$165,508 million per year. The average
total real GDP over that same period was
$6,670,909 million, and the 1998 real
GDP was $7,551,540 million (83). If
economic science can only explain about
50% of this growth, then the balance, or
residual, that is unexplained except in
terms of technical change as discussed
above amounts to $82,754 million (1992
dollars) per year. 
Because the quality of human capital
and labor, both intellectual and physical,
contributes to the determination and real-
ization of potential output, the changes in
that quality, through changes in the aver-
age IQ (our example is 5%), associated
changes in the contents of the extremes of
the distribution (and other cognitive and
behavioral deﬁcits), would also contribute
to changes, or the growth, in that output.
If this lost, or negative technical change,
contribution of the human capital to the
total residual were only 10%, hypotheti-
cally, this would create a loss of about
$8.3 billion (1992 dollars) a year in the
realized growth portion alone. 
• Similarly, if this lost or negative technical
change contribution of the human capital
to the total residual were 50%, the loss
would be almost $41 billion a year. In
terms of current dollars, the residual cal-
culated for the same period is almost
$171 billion, and the hypothetical loss at
10% is $17.1 billion per year, and at 50%
is about $85 billion per year. This hypo-
thetical example considers only a part of
the average amount of the recent growth
at the margin and does not consider possi-
ble impacts on the total output and over
an extended time. 
• For Canada, similar calculations yield an
average absolute growth in real (1992
CDN dollars) GDP over the 1990–1999
period of almost $18 billion per year, and
an average real GDP of $765 billion (79).
The residual here is $9 billion per year,
and the analogous loss would be $900
million at the 10% contribution and $4.5
billion at the 50% contribution. In cur-
rent dollars, the average growth in
absolute terms was $28 billion per year,
for a residual of $14 billion, on top of an
average $793 billion total GDP. This
implies that in current dollars, the losses
would be $1.4 billion or $7 billion per
year, respectively.
Real growth in output and growth in
productivity measured as real GDP per man-
hour worked have been declining steadily
from 1960 to the present in the United
States. In Canada, the growth rates in real
GDP have also been falling steadily from
1961; however, data on productivity indicate
a slow increase from 1976 to 1999. The data
reflect the well-known trends in these vari-
ables and the inability of economics to pro-
vide general, empirical explanations for the
observed trends. 
It is a reasonable hypothesis, however,
that negative changes in the quality of human
capital are at least partly responsible for these
declines. At least one report concludes that
there has been a serious and continuing man-
power quality decline in the United States
due to the ecologic changes and biologic
stresses to which individuals born there were
exposed during the several decades before the
report’s publication (67). For example, in the
United States real GDP grew by 50% from
1960 to 1969, then by just 37% from 1969
to 1979, by 31% from 1979 to 1989, and
ﬁnally by 25% from 1989 to 1998. The aver-
age per-year growth rates over those same
periods were, 4.6, 3.2, 2.8, and 2.5%, respec-
tively (83). Similarly for the productivity
measure, real GDP per man-hour grew in
total by 82% from 1960 to 1998. However,
from 1960 to 1969 it grew at an average of
2.7% per year, from 1969 to 1979 it grew at
1.9% per year, from 1979 to 1989 it grew by
1.1% per year, and from 1989 to 1998 it
grew at 1.0% per year. In Canada, the real
GDP grew by 55% from 1960 to 1969, by
50% from 1970 to 1979, by 31.5% from
1980 to 1989, and by 24.8% from 1990 to
1999. Annual growth rates are likewise falling
for these time periods (79). Productivity in
Canada grew by 29% from 1976 to 1999,
and by an average 0.35% per year from 1976
to 1979, by 1.1% from 1980 to 1989, and by
1.4% from 1990 to 1999.
Discussion and Summary
This review has reported evidence for concern
that environmental agents are causing clinical
disease in humans, and that children are at
particular risk. The authors found that
methodologies exist to document and esti-
mate the societal, economic, and personal
costs associated with this environmentally
related disease and have reviewed and
reported on several studies that have provided
such estimates. In most cases, the results pre-
sented are not new but reﬂect existing studies
and data. In other cases, we have attempted
to modify and extend the economic analysis
in order to consider other aspects thought to
be important. In some cases, the economic
links and costs attributed to the effect or out-
come are based on plausibility and hypotheti-
cal methods because the data and real
methods do not exist to permit an empirical
determination.
In this report we have also tried to apply
these techniques and approaches in a limited
way to four selected effects or outcomes, as
case studies that are thought to have some
environmental etiology. However, the report
makes no definite attribution of any of the
case-study effects to any particular environ-
mental toxic substance, persistent toxic
substance, or other pollutant or agent. 
In the summary discussion below, the
hypothesis-generating approach will be
applied to an aggregation of the results that
were put into a form of economic dollar cost.
As a form of thought provocation, reasoned
and hypothetical estimates of proportions of
the case-study effects or outcomes due to
environmental causes will be made.
Table 9 and the case-study tables in
Appendix A are a compilation of all the costs
that were identified or estimated for each
case-study effect, and for each jurisdiction.
The tables are structured to show the identiﬁ-
cation of societal or economic costs and
impacts and jurisdictions for which data were
found or could be estimated with relative
ease. These data are very incomplete in most
cases, either by type of cost or by jurisdiction. 
It is beyond the scope of this review to fac-
tually determine what proportion of the grand
total cost is attributable to environmental
causes such as toxic substances, persistent toxic
substances, and other chemical and physical
agents. Most, if not all, of these diseases are
multifactorial and may involve an environ-
ment–genetic interaction. However, some of
these diseases appear to be of recent origin,
that is, postindustrial age (e.g., Parkinson’s dis-
ease), or are of epidemic proportions (e.g., dia-
betes and childhood developmental disorders),
or have recent, large increases in prevalence. In
all cases it seems very little is really agreed upon
about what actually causes or triggers the dis-
ease; however, there are known associations in
all cases with environmental agents. In general,
a low proportion of cases is explainable by
known risk factors, perhaps around 30% or
less. These risk factors include genetics, diet,
smoking, and occupation. However, as we
learn more we ﬁnd that these factors can have
important environment interactions and
cumulative effects, may be cofactors, and may
be downstream in time in the causal process. 
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In the absence of a speciﬁc determination
of the proportion of the diseases that are
explained by either environmental or other
causes, one can only posit reasonable and
alternative hypotheses about these propor-
tions. A great many toxic and neurotoxic
agents circulate freely in the environment. All
people and potential progeny are constantly
exposed to these complex mixtures, and the
situation has not changed for many decades.
Given this reality, it is neither reasonable nor
prudent to assume that all these agents
together have a zero effect on the human
population. 
Participants at the IJC workshop were
asked if they thought there were zero effects;
no one responded in the affirmative.
Therefore, it would seem reasonable to posit
that at least 10% of these costs are due to
environmental causes. That would yield a
minimum attributable cost of $57 billion to
$79 billion per year.
If one were to consider the likelihood that
some of these diseases have a greater than
average environmental causation (e.g.,
Parkinson’s disease, childhood developmental
disorders, IQ decrements, and possibly dia-
betes), then a reasoned argument can be
made to increase the proportion of the costs
due to environmentally induced disease. A
hair-splitting solution would apportion the
prevalence equally, so a 50% proportion
would emerge that way. This involves an
attributable cost for the subject case studies of
between $283 billion and $397 billion per
year. The dynamic economic impacts on
growth and development considered above
and already based on a 10 and 50% propor-
tion are also proportioned here again by the
10 and 50% applied to the cumulative grand
total. This adds a measure of conservatism to
the attributable costs proposed above. 
At the current stage of research, appor-
tionment cannot proceed much further.
While some further evidence on causation
and association could be brought forward, as
noted, that is beyond the scope of the pre-
sent work. A forum is needed for bringing
this kind of debate to the floor. It may be
possible for knowledgeable people to make
such a preliminary determination on the
basis of the weight of evidence, a move we
recommend here. The effort should ulti-
mately consider the entire burden of human
disease from this perspective.
Conclusion 
The purpose of this study was to assemble
societal and economic cost information for a
suite of case-study effects or outcomes that
evidence shows to be candidates for the term
“environmental disease.” We found that the
economic and social costs associated with
these case studies are very large, even though
this report was only able to capture or esti-
mate a proportion of the real costs for
Canada and the United States. It is also rea-
sonable to expect that some of these costs are
directly attributable to chemical and physical
agents in the environment, of which there are
so many that it is not reasonable in this study
to make speciﬁc attributions.
It would be useful to assemble knowl-
edgeable people to weigh the evidence, and to
involve transdisciplinary methods, in an effort
to form a reasonable estimate of the likely
environmental burden of diseases such as
those considered here. In addition, more
work is needed to expand the scope of the
review and analysis reported here. The entire
burden of human disease should be consid-
ered in terms of environmental causation as a
preventable factor. Accounting for the eco-
nomic and social costs can contribute to a
better understanding of the real scope of the
many issues raised by polluted environments.
Table 9. Total cumulative costs identiﬁed.
Total actual health care expenditures per year (Canada and U.S.) $1.362 trillion
Cost of diabetes (Canada and U.S.) $127.857 billion annually
Cost of Parkinson’s disease annually (Ontario and U.S.) $13.018 to $28.518 billion 
Cost of hypothyroidism (Ontario) $8.691 million annually
Costs associated with neurodevelopmental effects (Ontario and  $83.301 billion to $169.176 billion annually
U.S.; plus Canada Ritalin costs)
Loss in earnings per IQ point decrement (Canada and U.S.) $61 billion to $71 billion annually
(1999 dollars)
Total income loss per year due to a hypothetical 5-point  $305 billion to $356 billion annually
IQ decrement (1999 dollars)
Costs associated with impacts on social costs (Ontario and U.S.) $19.86 billion annually
Cost of dynamic economic impacts on growth and development 
(Canada and U.S.)
Decline of 10% of the residual $18.5 billion (current dollars) annually
Decline of 50% of the residual $92 billion (current dollars) annually
Total cumulative costs identiﬁed (Canada and Ontario) $48.135 billion to $53.901 billion (CDN dollars)
Total cumulative costs identiﬁed (U.S.) $519.409 billion to $739.518 billion (U.S. dollars)
Grand total of cumulative costs identiﬁeda (does not include  $567.545 billionb to $793.420 billionc annually 
total health care expenditures)
aA decision was made not to convert this grand total of cumulative costs identiﬁed to a common currency, as this would be distorting
and misleading for a variety of reasons. bBased on the lower limit of the cost of Parkinson’s disease, the lower limit in the loss in
earnings per 5-point IQ decrement, and the decline of 10% of the residual in the calculation of the cost of the dynamic economic
impacts on growth and development. cBased on the upper limit of the cost of Parkinson’s disease, the upper limit in the loss in earn-
ings per 5-point IQ decrement, and the decline of 50% of the residual in the calculation of the cost of the dynamic economic impacts
on growth and development. Societal costs of exposure to toxic substances
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Table A1. Total cumulative costs identiﬁed, United States.a
Healthcare expenditures $1.276 trillion 
Cost of diabetes $113.7 billion annually
Speciﬁc costs related to Parkinson’s disease  $13 billion to $28.5 billion annually
Other sources of cost data on Parkinson’s disease $25 billion annually 
Cost of hypothyroidism —
Costs associated with neurodevelopmental effects $81.479 to $167.188 billion annually
Loss in earnings per 1-point IQ decrement $55 billion to $65.4 billion annually
Total income loss per year due to a 5-point IQ decrement  $275 billion to $326 billion annually
Costs associated with impacts on social costs $19.13 billion
Cost of dynamic economic impacts on growth and development
Decline of 10% of residual $8.3 billion annually (real 1992 U.S. dollars)
$17.1 billion annually (current U.S. dollars)
Decline of 50% of residual $41 billion annually (real 1992 U.S. dollars)
$85 billion annually (current U.S. dollars)
Total cumulative costsb $519.409 billionc to $739.518 billiond
aAll data in 1999 U.S. dollars unless otherwise stated. bTotal cumulative costs identiﬁed does not include total health care expendi-
tures and the identiﬁed $25 billion cost of Parkinson’s disease from other sources. Instead the range in total cumulative costs identi-
ﬁed is based on the range in speciﬁc cost data related to Parkinson’s disease ($13 billion to $28.5 billion). cBased on the lower limit of
the loss in earnings per 5-point IQ decrement, the lower limit of other costs related to Parkinson’s, the low limit of costs associated
with neurodevelopmental effects and hypothyroidism and the decline of 10% of the residual, based on current dollars, in the calcula-
tion of the cost of dynamic economic impacts on growth and development. dBased on the upper limit of the loss in earnings per
5-point IQ decrement the upper limit of other costs related to Parkinson’s disease, the upper limit of costs associated with neurodevel-
opmental effects and hypothyroidism and the decline of 50% of the residual, based on current dollars, in the calculation of the cost of
dynamic economic impacts on growth and development.
Table A2. Cumulative costs identiﬁed, Canada.
Healthcare expenditures $86 billion (1999 CDN dollars)
Cost of diabetes $14.157 billion annually (1999 CDN dollars)
Cost of Parkinson’s disease —
Other costs related to Parkinson’s disease —
Cost of hypothyroidism —
Costs associated with neurodevelopmental effects $50.018 million annually
Loss in earnings per 1-point IQ decrement $6 billion annually (1999 CDN dollars)
Total income loss per year due to a 5-point IQ decrement  $30 billion annually (1999 CDN dollars)
Costs associated with impacts on social costs $590.24 million annually
Cost of dynamic economic impacts on growth and development
Decline of 10% of residual $900 million annually (real 1992 CDN dollars)
$1.4 billion annually (current CDN dollars)
Decline of 50% of residual $4.5 billion annually (real 1992 CDN dollars)
$7 billion annually (current CDN dollars)
Total cumulative costs identiﬁed (not including total  $46.197 billiona to $51.797 billionb
healthcare expenditures)
aBased on the lower limit of the loss in earnings per 5-point IQ decrement and the decline of 10% of the residual, based on current
dollars, in the calculation of the cost of dynamic economic impacts on growth and development. bBased on the upper limit of the loss
in earnings per 5-point IQ decrement and the decline of 50% of the residual, based on current dollars, in the calculation of the cost of
dynamic economic impacts on growth and development. 
Appendix
The Appendix is a detailed compilation of costs identiﬁed or estimated for each case study, by jurisdiction.
Table A3. Total cumulative costs identiﬁed, Ontario (these are not included in the total cumulative costs identiﬁed
for Canada).
Healthcare expenditures $30.4 billion (1999 CDN dollars)
Cost of diabetes $109.7 million annually
Cost of Parkinson’s disease $17.7 million annually
Other costs related to Parkinson’s disease —
Cost of hypothyroidism $8.691 million annually
Costs associated with neurodevelopmental effects $1.772 billion to $1.938 billion annually
Loss in earnings per 1-point IQ decrement $2.3 billion annually (1999 CDN dollars)
Total income loss per year due to a 5-point IQ decrement  $11.5 billion annually (1999 CDN dollars)
Costs associated with impacts on social costs $730.56 million annually 
Cost of dynamic economic impacts on growth and development
Decline of 10% of residual —
Decline of 50% of residual —
Total cumulative costs identiﬁed (not including total  $14.139 billiona to $14.305 billion annually b
healthcare expenditures)
aBased on the loss in earnings per 5-point IQ decrement and the lower limit of the costs associated with neurodevelopmental effects
and hypothyroidism. bBased on the loss in earnings per 5-point IQ decrement and the upper limit of the costs associated with neuro-
developmental effects and hypothyroidism.Muir and Zegarac
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Table A4. Total cumulative costs identiﬁed. 
Healthcare expenditures
Actual national healthcare expenditures 
U.S. $1.276 trillion (1999 U.S. dollars) or $4,640 per person
Canada $86 billion (1999 CDN dollars) or $2,800 per person, 9.2% of GDP
Actual provincial healthcare expenditures (Ontario) $30.4 billion (1999 CDN dollars) or $2,772 per person
Diabetes
United States
Total direct medical and indirect expenditures (including lost productivity) $113.7 billion (1999 U.S. dollars)
Direct medical expenditures $51.2 billion
Indirect costs $63.12 billion
Canada
Burden of diabetes medical care alone (incomplete study) $1.18 billion (1999 CDN dollars)
Complete estimate may be as high as this ﬁgure (based on 10% of 1998 U.S.  $14.157 billion (1999 CDN dollars)
expenditures, modiﬁed to CDN dollars then updated to 1999 dollars)
Ontario
Inpatient and outpatient hospital costs (OHIP) $54.4 million (CDN dollars) annually, 1996–1998
Doctors’ costs (OHIP) $55.3 million (CDN dollars), 1998/1999
Cost of diabetes (U.S.) $113.7 billion (1999 U.S. dollars) annually
Cost of diabetes (Canada) $14.157 billion (1999 CDN dollars) annually
Cost of diabetes (Ontario) $109.7 million (CDN dollars)
Parkinson’s disease
Parkinson’s disease (Ontario)
Inpatient and outpatient hospital costs (OHIP) $14.2 million (CDN dollars) annually (based on 1996–1998)
Average cost per case of almost $16,400
Doctors’ costs (OHIP) $3.5 million (CDN dollars), 1998/1999
Identiﬁed speciﬁc costs related to PD (U.S.) (1999 U.S. dollars)
L-Dopa and related drugs $400 million to $3.6 billion annually (based on 400,000–600,000 PD patients at a
cost of $1,000–$6,000 annually, per patient)
Typical early-stage annual medical cost $800 million to $4.2 billion annually (based on 400,000–600,000 PD patients at a
cost of $2,000–$7,000 per patient (advanced cases run higher)
Treatment and hospitalization for PD-caused falls $6.1 billion to $9.1 billion annually 
$40,000 or more per patient
38% of PD sufferers fall; 13% fall more than once a week
Disability income $3.7 billion to $5.6 billion annually
$30,000 or more annually per case of lost employment
31% of PD sufferers employed will lose employment within a year
Assisted living and nursing home care
Assuming 5% of patients become disabled $2 billion to $3 billion annually; $100,000 or greater per patient annually 
Assuming 10% of patients become disabled $4 billion to $6 billion annually; $100,000 or greater per patient annually
Other sources of cost data on PD (U.S.) (1999 U.S. dollars) 
Annual cost of PD (identiﬁed in testimony before the U.S. Senate $25 billion annually
Committee on Aging)
PD has signiﬁcantly higher mean total expenditure PD: $22,914; control: $10,458 
PD patients had higher mean prescription and home healthcare Prescription ($882 higher)
provider expenditures Home health provider ($441 higher)
Parkinson’s disease (France, Germany, other) (1999 U.S. dollars)
Estimated annual cost of PD, France $411 million ($5,129 average cost × 80,000 PD cases)
Medical cost of PD, Germany $4,410 (3-month period)
Drug expenses for several countries, including the U.S. $342 million (1996 OECD data)
Total identiﬁed costs related to PD (U.S.) $13 billion to $28.5 billion (1999 U.S. dollars) annually
Identiﬁed cost of PD (Ontario; not available for Canada) $17.7 million (CDN dollars) annually
Hypothyroidism
Hypothyroidism (Ontario)
Hospital treatment (OHIP) $591,000 (CDN dollars) annually or $3,400 per case (based on 1996–1998 data)
Doctors’ costs (OHIP) $8.1 million (CDN dollars), 1998–1999
Total cost of hypothyroidism (Ontario) $8.691 million annually
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Table A4. Continued.
Costs associated with neurodevelopmental effects, with hypothyroidism as a suggested mechanism
ADHD, autism, dyslexia, and assorted learning disorders
Hospital treatment (OHIP) $1 million (CDN dollars) per year (based on 1996–1998)
Doctors’ costs (OHIP) $8.4 million (CDN dollars) 1998–1999
Ritalin $50.018 million (CDN dollars); 56.2 million pills sold in Canada in 1998
Education (1999 dollars)
Special education (Ontario Ministry of Education) Budgeted $1.218 billion or $6,477 per student (1999–2000)
Special education (Hamilton–Wentworth District School Board) $7,660 per student (shortfall had to be diverted from other allocation)
Autistic child (cost to family) $17,000 (and more) annually (not paid by healthcare system in Ontario)
Autistic children (Ontario) (cost to families)
Based on 3,000–5,000 autistic children $51 million to $85 million annually
Based on 13,300 children $226 million annually
Correctional services (1999 CDN dollars): cost of custody for young offenders (Ontario)
50% closed custody population $473,289,790 annual cost
50% open custody population $11,255,396 annual cost
Total costs associated with neurodevelopmental effects 
Ontario $1.772 billion to $1.938 billion annually (CDN dollars)
Canada—Ritalin only; excludes Ontario above $50.018 million annually (CDN dollars)
Estimated costs of neurodevelopmental effects (U.S.) (1999 dollars)
Special education $78 billion to $92 billion annually (12 million children × $6,477 and $7,660, respectively)
$130 billion to $150 billion annually (20 million with developmental brain disorders)
Ritalin $1.949 billion annually (2.190 billion pills at $0.89 each)
$10.388 billion annually [assumes 8 million children using Ritalin at 
$25 (CDN dollars)/week/child]. Note: anecdotal estimates put drugs at up to $50/week
Autistic children (U.S.) (cost to families) $1.53 billion to $2.55 billion annually (90,000–150,000 cases, based on Ontario 
prevalence) (assumes Ontario cost per case of $17,000)
$6.8 billion annually (based on autism spectrum disorders affecting 400,000)
Total identiﬁed costs associated with neurodevelopmental effects (U.S.)  $81.479 billion to $167.188 billion annually
(1999 U.S. dollars)
Costs associated with neurodevelopmental effects and IQ
Estimated costs of neurodevelopmental effects and IQ, United States (1987 U.S. dollars)
Loss in earnings per 1-point IQ decrement $20.7 billion annually ($5,307 × 3.9 million); Schwartz (17)
$33.4 billion annually ($6,303 males and $10,929 females) [Salkever (18)]
Total income loss per year due to a hypothetical 5-point IQ decrement $104 billion annually [Schwartz (17)]
$167 billion annually [Salkever (18)]
Estimated costs of neurodevelopmental effects and IQ, United States (1999 U.S. dollars)
Loss in earnings per 1-point IQ decrement $55 billion annually ($13,680 × 4.02 million) [Schwartz (17)]
$65.4 billion annually ($17,098 males and $15,263 females) [Salkever (18)]
Total income loss per year due to a hypothetical 5-point IQ decrement $275 billion [Schwartz (17)]
$327 billion [Salkever (18)]
Estimated costs of neurodevelopmental effects and IQ (Canada and Ontario) (1999 CDN dollars)
Loss in earnings per 1-point IQ decrement (based on Salkever coefﬁcients)
Canada $6 billion annually (CDN dollars)
Ontario $2.3 billion annually (CDN dollars)
Total income loss per year due to a hypothetical 5-point IQ decrement
Canada $30 billion annually (CDN dollars)
Ontario $11.5 billion annually (CDN dollars)
Loss in earnings per 1-point IQ decrement
Canada $6 billion annually (1999 CDN dollars)
Ontario $2.3 billion annually (1999 CDN dollars)
United States $55 billion to $65 billion annually (1999 U.S. dollars)
Total income loss per year due to a hypothetical 5-point IQ decrement
Canada $30 billion annually (1999 CDN dollars)
Ontario $11.5 billion annually (1999 CDN dollars)
United States $275 billion to $327 billion annually (1999 U.S. dollars)
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Table A4. Continued.
Impacts on social costs
Low-weight births United States (1999 U.S. dollars)
Costs of low-weight births among children from birth to age 15 $7.2 billion annually
Additional costs associated with low-weight births to age 15 $2.53 billion annually 
Increase in low-weight births due to loss of 3 IQ points $1.17 billion annually (assumes 12% increase in low-weight births)
Canada and Ontario (1999 CDN dollars)
Cost of low-weight births among children from birth to age 15
Canada $527 million annually (21,602 low-weight births 1995/1996)
Ontario $213 million annually (8,728 low-weight births 1995/1996)
Increase in low-weight births due to loss of 3 IQ points
Canada $63.24 million annually (assumes 12% increase in low-weight births)
Ontario $25.56 million annually
Welfare (Ontario)
18% increase in welfare recipients due to a 3% decrease in average IQ $255 million annually (average unweighted beneﬁt level in 1997 was $12,600
Total welfare cost estimate of $14.15 billion annually
Correctional services
U.S. (1999 U.S. dollars): 25% increase in the number of males incarcerated $8.23 billion annually 
due to 3% decrease in average IQ In 1996 1.7 million persons were incarcerated at a cost of $30 billion
Ontario (1999 CDN dollars): 25% increase in number of young male offenders $237 million annually
incarcerated due to 3% decrease in average IQ Cost of young offender services in 1999–2000 was about $947 million annually
Costs associated with impacts on social costs
Canada $590.24 million annually (1999 CDN dollars)
Ontario $730.56 million annually (1999 CDN dollars)
United States $19.13 billion annually (1999 U.S. dollars)
Dynamic economic impacts on growth and development
United States
Decline of 10% of the residuala $8.3 billion annually (real 1992 U.S. dollars) (average growth in real GDP 1990–1998 
was $165.5 billion)
$17.1 billion annually (current U.S. dollars)
Decline of 50% of the residual $41 billion annually (real 1992 U.S. dollars)
$85 billion annually (current U.S. dollars)
Canada
Decline of 10% of the residual $900 million annually (real 1992 CDN dollars) (average growth in real GDP 1990–1999 
was $18 billion)
$1.4 billion annually (current CDN dollars)
Decline of 50% of the residual $4.5 billion annually (real 1992 CDN dollars)
$7 billion annually (current CDN dollars)
aThe part of growth in output that cannot be explained by the increase in capital, as well as other factors, is referred to as the “residual”. This residual was attributed to a general term noted as “technical
change” or technical progress, which is itself composed of improvements in the quality of the various forms of conventional inputs. The “residual” is based on the average real (adjusted for inﬂation) or
current GDP, between the period 1990 to 1998 for the U.S., and between the period 1990 to 1999 for Canada. Note: GDP data for the U.S. was only available up to 1998.Societal costs of exposure to toxic substances
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